UnitedHealth (UNH) 10-K 27 Feb 25 2024 FY Annual report Financial data

Cover Document

Cover Document - USD ($)	12 Months Ended
	Dec. 31, 2024	Jan. 31, 2025	Jun. 30, 2024
Cover Page [Abstract]
Entity File Number	1-10864
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false
Document Transition Report	false
Entity Registrant Name	UnitedHealth Group Incorporated
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1321939
Entity Address, Address Line One	1 Health Drive
Entity Address, City or Town	Eden Prairie,
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
Other Address, Address line one	655 New York Avenue NW
Other Entity Address, City or Town	Washington,
Other Entity Address, State or Province	DC
Other Entity Address, Postal Zip Code	20001
City Area Code	800
Local Phone Number	328-5979
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	UNH
Security Exchange Name	NYSE
Well known seasoned issuer	Yes
Entity Voluntary Filers	No
Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Public Float			$ 468,433,146,650
Entity Common Stock, Shares Outstanding		914,712,333
Documents Incorporated by Reference	The information required by Part III of this report, to the extent not set forth herein, is incorporated by reference from the registrant’s definitive proxy statement relating to its 2025 Annual Meeting of Shareholders. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
Entitiy Central Index Key	0000731766
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false

Auditor Information

Auditor Information	12 Months Ended
	Dec. 31, 2024
Auditor Information [Abstract]
Auditor Name	DELOITTE & TOUCHE LLP
Auditor Firm ID	34
Auditor Location	Minneapolis, Minnesota

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 25,312	$ 25,427
Short-term investments	3,801	4,201
Accounts receivable, net of allowances of $985 and $1,000	22,365	21,276
Other current receivables, net of allowances of $2,864 and $2,084	26,089	17,694
Assets under management	0	3,755
Prepaid expenses and other current assets	8,212	6,084
Total current assets	85,779	78,437
Long-term investments	52,354	47,609
Property, equipment and capitalized software, net of accumulated depreciation and amortization of $6,971 and $7,039	10,553	11,450
Goodwill	106,734	103,732
Other intangible assets, net of accumulated amortization of $8,350 and $7,279	23,268	15,194
Other assets	19,590	17,298
Total assets	298,278	273,720
Current liabilities:
Medical costs payable	34,224	32,395
Accounts payable and accrued liabilities	34,337	31,958
Short-term borrowings and current maturities of long-term debt	4,545	4,274
Unearned revenues	3,317	3,355
Other current liabilities	27,346	27,072
Total current liabilities	103,769	99,054
Long-term debt, less current maturities	72,359	58,263
Deferred income taxes	3,620	3,021
Other liabilities	15,939	14,463
Total liabilities	195,687	174,801
Commitments and contingencies (Note 12)
Redeemable noncontrolling interests	4,323	4,498
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value - 3,000 shares authorized; 915 and 924 issued and outstanding	9	9
Retained earnings	96,036	95,774
Accumulated other comprehensive loss	(3,387)	(7,027)
Nonredeemable noncontrolling interests	5,610	5,665
Total equity	98,268	94,421
Total liabilities, redeemable noncontrolling interests and equity	$ 298,278	$ 273,720

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - USD ($) shares in Millions, $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Allowance for doubtful accounts, accounts receivable	$ 985	$ 1,000
Allowance for doubtful accounts, other receivables	2,864	2,084
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	6,971	7,039
Finite-lived Intangible Assets, Accumulated Amortization	$ 8,350	$ 7,279
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10	10
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000	3,000
Common stock, shares issued	915	924
Common Stock, Shares, Outstanding	915	924

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Premiums	$ 308,810	$ 290,827	$ 257,157
Investment and other income	5,202	4,089	2,030
Total revenues	400,278	371,622	324,162
Operating costs:
Medical costs	264,185	241,894	210,842
Operating costs	53,013	54,628	47,782
Cost of products sold	46,694	38,770	33,703
Depreciation and amortization	4,099	3,972	3,400
Total operating costs	367,991	339,264	295,727
Earnings from operations	32,287	32,358	28,435
Interest expense	(3,906)	(3,246)	(2,092)
Loss on sale of subsidiary and subsidiaries held for sale	(8,310)	0	0
Earnings before income taxes	20,071	29,112	26,343
Provision for income taxes	(4,829)	(5,968)	(5,704)
Net earnings	15,242	23,144	20,639
Earnings attributable to noncontrolling interests	(837)	(763)	(519)
Net earnings attributable to UnitedHealth Group common shareholders	$ 14,405	$ 22,381	$ 20,120
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic	$ 15.64	$ 24.12	$ 21.47
Diluted	$ 15.51	$ 23.86	$ 21.18
Basic weighted-average number of common shares outstanding	921	928	937
Dilutive effect of common share equivalents	8	10	13
Diluted weighted-average number of common shares outstanding	929	938	950
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents	6	6	3
Products
Revenues:
Revenue from Products and Services	$ 50,226	$ 42,583	$ 37,424
Services
Revenues:
Revenue from Products and Services	$ 36,040	$ 34,123	$ 27,551

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net earnings	$ 15,242	$ 23,144	$ 20,639
Other comprehensive income (loss):
Gross unrealized gains (losses) on investment securities during the period	29	1,139	(4,292)
Income tax effect	(7)	(263)	984
Total unrealized gains (losses), net of tax	22	876	(3,308)
Gross reclassification adjustment for net realized (gains) losses included in net earnings	(369)	(90)	139
Income tax effect	92	21	(32)
Total reclassification adjustment, net of tax	(277)	(69)	107
Foreign currency translation (losses) gains	(319)	559	192
Reclassification adjustment for translation losses included in net earnings	4,214	0	0
Total foreign currency translation gains	3,895	559	192
Other comprehensive income (loss)	3,640	1,366	(3,009)
Comprehensive income	18,882	24,510	17,630
Comprehensive income attributable to noncontrolling interests	(837)	(763)	(519)
Comprehensive income attributable to UnitedHealth Group common shareholders	$ 18,045	$ 23,747	$ 17,111

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Net Unrealized Gains (Losses) on Investments [Member]	Foreign Currency Translation (Losses) Gains [Member]	Noncontrolling Interest
Balance at Dec. 31, 2021	$ 75,045	$ 10	$ 0	$ 77,134	$ 423	$ (5,807)	$ 3,285
Balance (in shares) at Dec. 31, 2021		941
Net earnings attributable to UnitedHealth Group common shareholders	20,120			20,120
Net earnings attributable to nonredeemable noncontrolling interest							406
Net earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	20,526
Other comprehensive (loss) income	(3,009)				(3,201)	192
Issuances of common stock, and related tax effects (in shares)		7
Issuances of common stock, and related tax effects	903	$ 0	903
Share-based compensation	875		875
Common share repurchases (in shares)		(14)
Common share repurchases	(7,000)	$ (1)	(1,892)	(5,107)
Cash dividends paid on common shares ($8.18 per share, $7.29 per share and $6.40 per share for the years ended December 31, 2024, 2023 and 2022, respectively)	(5,991)			(5,991)
Redeemable noncontrolling interests fair value and other adjustments	114		114
Acquisition and other adjustments of nonredeemable noncontrolling interests	374						374
Distributions to nonredeemable noncontrolling interests	(387)						(387)
Balance at Dec. 31, 2022	81,450	$ 9	0	86,156	(2,778)	(5,615)	3,678
Balance (in shares) at Dec. 31, 2022		934
Net earnings attributable to UnitedHealth Group common shareholders	22,381			22,381
Net earnings attributable to nonredeemable noncontrolling interest							575
Net earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	22,956
Other comprehensive (loss) income	1,366				807	559
Issuances of common stock, and related tax effects (in shares)		6
Issuances of common stock, and related tax effects	1,231	$ 0	1,231
Share-based compensation	$ 1,027		1,027
Common share repurchases (in shares)	(16)	(16)
Common share repurchases	$ (8,059)	$ 0	(2,057)	(6,002)
Cash dividends paid on common shares ($8.18 per share, $7.29 per share and $6.40 per share for the years ended December 31, 2024, 2023 and 2022, respectively)	(6,761)			(6,761)
Redeemable noncontrolling interests fair value and other adjustments	(201)		(201)
Acquisition and other adjustments of nonredeemable noncontrolling interests	1,928						1,928
Distributions to nonredeemable noncontrolling interests	(516)						(516)
Balance at Dec. 31, 2023	$ 94,421	$ 9	0	95,774	(1,971)	(5,056)	5,665
Balance (in shares) at Dec. 31, 2023	924	924
Net earnings attributable to UnitedHealth Group common shareholders	$ 14,405			14,405
Net earnings attributable to nonredeemable noncontrolling interest							663
Net earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	15,068
Other comprehensive (loss) income	3,640				(255)	3,895
Issuances of common stock, and related tax effects (in shares)		8
Issuances of common stock, and related tax effects	1,485	$ 0	1,485
Share-based compensation	$ 963		963
Common share repurchases (in shares)	(17)	(17)
Common share repurchases	$ (9,005)	$ 0	(2,395)	(6,610)
Cash dividends paid on common shares ($8.18 per share, $7.29 per share and $6.40 per share for the years ended December 31, 2024, 2023 and 2022, respectively)	(7,533)			(7,533)
Redeemable noncontrolling interests fair value and other adjustments	(53)		(53)
Acquisition and other adjustments of nonredeemable noncontrolling interests	26						26
Distributions to nonredeemable noncontrolling interests	(744)						(744)
Balance at Dec. 31, 2024	$ 98,268	$ 9	$ 0	$ 96,036	$ (2,226)	$ (1,161)	$ 5,610
Balance (in shares) at Dec. 31, 2024	915	915

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity (Parenthetical) - $ / shares					12 Months Ended
	Dec. 17, 2024	Sep. 24, 2024	Jun. 25, 2024	Mar. 19, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash dividends per common share	$ 2.10	$ 2.10	$ 2.10	$ 1.88	$ 8.18	$ 7.29	$ 6.40

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating activities
Net earnings	$ 15,242	$ 23,144	$ 20,639
Noncash items:
Depreciation and amortization	4,099	3,972	3,400
Deferred income taxes	(296)	(245)	(673)
Share-based compensation	1,018	1,059	925
Loss on sale of subsidiary and subsidiaries held for sale	8,310	0	0
Gains on dispositions and other strategic transactions	(3,333)	(489)	(588)
Other, net	(28)	(16)	257
Net change in other operating items, net of effects from acquisitions and dispositions:
Accounts receivable	(1,437)	(3,114)	(2,523)
Other assets	(4,140)	(2,444)	(1,374)
Medical costs payable	2,503	3,482	4,053
Accounts payable and other liabilities	2,463	3,516	1,964
Unearned revenues	(197)	203	126
Cash flows from operating activities	24,204	29,068	26,206
Investing activities
Purchases of investments	(27,308)	(18,314)	(18,825)
Sales of investments	18,514	7,307	5,907
Maturities of investments	9,319	9,230	6,081
Cash paid for acquisitions and other transactions, net of cash assumed	(13,408)	(10,136)	(21,458)
Purchases of property, equipment and capitalized software	(3,499)	(3,386)	(2,802)
Loans to care providers - cyberattack	(9,033)	0	0
Repayments of care provider loans - cyberattack	4,514	0	0
Cash received from dispositions and other strategic transactions, net	2,041	685	3,414
Other, net	(1,667)	(960)	(793)
Cash flows used for investing activities	(20,527)	(15,574)	(28,476)
Financing activities
Common share repurchases	(9,000)	(8,000)	(7,000)
Cash dividends paid	(7,533)	(6,761)	(5,991)
Proceeds from common stock issuances	1,846	1,353	1,253
Repayments of long-term debt	(3,000)	(2,125)	(3,015)
(Repayments of) proceeds from short-term borrowings, net	(151)	11	732
Proceeds from issuance of long-term debt	17,811	6,394	14,819
Customer funds administered	(1,560)	(521)	5,548
Purchases of redeemable noncontrolling interests	(280)	(730)	(176)
Other, net	(1,645)	(1,150)	(1,944)
Cash flows (used for) from financing activities	(3,512)	(11,529)	4,226
Effect of exchange rate changes on cash and cash equivalents	(61)	97	34
Increase in cash and cash equivalents, including cash within businesses held for sale	104	2,062	1,990
Less: cash within businesses held for sale	(219)	0	0
Net (decrease) increase in cash and cash equivalents	(115)	2,062	1,990
Cash and cash equivalents, beginning of period	25,427	23,365	21,375
Cash and cash equivalents, end of period	25,312	25,427	23,365
Supplemental cash flow disclosures
Cash paid for interest	3,594	3,035	1,945
Cash paid for income taxes	$ 4,620	$ 6,078	$ 5,222

Description of Business (Notes)

Description of Business (Notes)	12 Months Ended
	Dec. 31, 2024
Nature of Operations [Text Block]	Description of Business UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.

Basis of Presentation, Uses of

Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Notes)	12 Months Ended
	Dec. 31, 2024
Basis of Presentation and Significant Accounting Policies [Text Block]	Basis of Presentation, Use of Estimates and Significant Accounting Policies Basis of Presentation The Company has prepared the Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. Use of Estimates These Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. Revenues Premiums Premium revenues are primarily derived from risk-based arrangements in which the premium is typically at a fixed rate per individual served for a one-year period, and the Company assumes the economic risk of funding its customers’ health care and related administrative costs. Premium revenues are recognized in the period in which eligible individuals are entitled to receive health care benefits. Health care premium payments received from the Company’s customers in advance of the service period are recorded as unearned revenues. Fully insured commercial products of U.S. health plans, Medicare Advantage and Medicare Prescription Drug Benefit (Medicare Part D) plans with medical loss ratios (MLRs) as calculated under the definitions in the Patient Protection and Affordable Care Act (ACA) and related federal and state regulations and implementing regulation, falling below certain targets are required to rebate ratable portions of their premiums annually. Commercial premiums within the Company’s individual and small group markets are also subject to the ACA risk adjustment program. Medicare Advantage premium revenue includes the impact of the Centers for Medicare & Medicaid Services (CMS) quality bonuses based on plans’ Star rating. Certain of the Company’s Medicaid business is also subject to state minimum MLR rebates. Premium revenues are recognized based on the estimated premiums earned, net of projected rebates, because the Company is able to reasonably estimate the ultimate premiums of these contracts. The Company also records premium revenues for certain value-based arrangements at its Optum Health care delivery businesses. Under these value-based arrangements, the Company enters into agreements with health plans to stand ready to deliver, integrate, direct and control certain health care services for patients. In exchange, the Company receives a premium that is typically paid on a per-patient per-month basis. The Company considers these value-based arrangements to represent a single performance obligation where premium revenues are recognized in the period in which health care services are made available. The Company’s Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under CMS’ risk adjustment payment methodology. CMS deploys a risk adjustment model which apportions premiums paid to all health plans according to health severity and certain demographic factors. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis and encounter data from hospital inpatient, hospital outpatient and physician treatment settings. The Company and health care providers collect, capture and submit the necessary and available data to CMS within prescribed deadlines. The Company estimates risk adjustment premium revenues based upon the data submitted and expected to be submitted to CMS. Risk adjustment data for the Company’s plans are subject to review by the government, including audit by regulators. See Note 12 for additional information regarding these audits. Products and Services For the Company’s Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors’ members and accordingly, product revenues are reported on a gross basis. Services revenue includes a number of services and products sold through Optum. Optum Health’s service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured for each period based on the progress to date as services are performed or made available to customers. Services revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees’ dependents. Under service fee contracts, the Company receives a monthly fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees’ dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period. As of December 31, 2024 and 2023, accounts receivables related to products and services were $9.9 billion and $8.6 billion, respectively. In 2024 and 2023, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2024 or 2023. For the years ended December 31, 2024, 2023 and 2022, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material. As of December 31, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $12.7 billion, of which approximately half is expected to be recognized in the next three years. See Note 14 for disaggregation of revenue by segment and type. Medical Costs and Medical Costs Payable The Company’s estimate of medical costs payable represents management’s best estimate of its liability for unpaid medical costs as of December 31, 2024. Each period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months. Medical costs and medical costs payable include estimates of the Company’s obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, care activity and other medical cost trends, membership volume and demographics, the introduction of new technologies, benefit plan changes and business mix changes related to products, customers and geography. In developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months. Cost of Products Sold The Company’s cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery, specialty and community pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to unaffiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those unaffiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance and professional services. Cash, Cash Equivalents and Investments Cash and cash equivalents are highly liquid investments having an original maturity of three months or less. The fair value of cash and cash equivalents approximates their carrying value because of the short maturity of the instruments. Investments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments are measured at fair value, with certain exceptions where the Company has elected to measure investments with unobservable inputs at cost, subject to fair value adjustments upon an impairment or a transaction of the same or similar security. Changes in fair value of equity investments are recognized in net earnings. The Company excludes unrealized gains and losses on available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold. The Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances which may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings. New information and the passage of time can change these judgments. The Company manages its investment portfolio to limit its exposure to any one issuer or market sector, and largely limits its investments to investment grade quality. Assets Under Management In July 2024, the Company amended its Medicare Supplement Program with a membership organization (the Medicare Supplement Program). The amendments provide the Company the right to use a trade name and other intellectual property in marketing efforts for Medicare Supplement offerings. Amounts previously reported as assets under management are now included within the Company’s Consolidated Balance Sheet based upon their classification. For periods prior to the amended Medicare Supplement Program, the Company excluded the effects of certain balance sheet amounts in its Consolidated Statements of Cash Flows, while these effects are included for periods after the amendments. Other Current Receivables Other current receivables include amounts due from pharmaceutical manufacturers for rebates and Medicare Part D drug discounts, loans to care providers in response to the Change Healthcare cyberattack, accrued interest and other miscellaneous amounts due to the Company. The Company’s pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers’ products by its affiliated and unaffiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2024 and 2023, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $12.5 billion and $11.0 billion, respectively. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets included pharmaceutical drug and supplies inventory of $3.8 billion and $2.8 billion as of December 31, 2024 and 2023, respectively. Property, Equipment and Capitalized Software Property, equipment and capitalized software are stated at cost, net of accumulated depreciation and amortization. Capitalized software consists of certain costs incurred in the development of internal-use software, including external direct costs of materials and services and applicable payroll costs of employees devoted to specific software development. The Company calculates depreciation and amortization using the straight-line method over the estimated useful lives of the assets. The useful lives for property, equipment and capitalized software are: Furniture, fixtures and equipment 3 to 10 years Buildings 35 to 40 years Capitalized software 3 to 5 years Leasehold improvements are depreciated over the shorter of the remaining lease term or their estimated useful economic life. Operating Leases The Company leases facilities and equipment under long-term operating leases which are non-cancelable and expire on various dates. At the lease commencement date, lease right-of-use (ROU) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period closely matching the lease term. The Company’s ROU assets are included in other assets, and lease liabilities are included in other current liabilities and other liabilities in the Company’s Consolidated Balance Sheet Goodwill To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs impairment tests. The Company may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital levels and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill. There was no impairment of goodwill during the years ended December 31, 2024, 2023 and 2022. Intangible Assets The Company’s finite-lived intangible assets are subject to impairment tests when events or circumstances indicate an intangible asset (or asset group) may be impaired. The Company’s indefinite-lived intangible assets are also tested for impairment annually. There was no impairment of intangible assets during the years ended December 31, 2024, 2023 and 2022. Other Current Liabilities Other current liabilities include health savings account deposits ($13.7 billion and $13.5 billion as of December 31, 2024 and 2023, respectively), accruals for premium rebates payable, the current portion of future policy benefits and customer balances. Policy Acquisition Costs The Company’s short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days’ notice. Costs related to the acquisition and renewal of short duration customer contracts are primarily charged to expense as incurred. Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside of the Company’s control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2024 and 2023: (in millions) 2024 2023 Redeemable noncontrolling interests, beginning of period $ 4,498 $ 4,897 Net earnings 174 188 Acquisitions 33 122 Redemptions (280) (730) Distributions (125) (144) Fair value and other adjustments 23 165 Redeemable noncontrolling interests, end of period $ 4,323 $ 4,498 Share-Based Compensation The Company recognizes compensation expense for share-based awards, including stock options and restricted stock and restricted stock units (collectively, restricted shares), on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. Restricted shares vest ratably, primarily over four four Net Earnings Per Common Share

Investments (Notes)

Investments (Notes)	12 Months Ended
	Dec. 31, 2024
Investments [Abstract]
Investments [Text Block]	Investments A summary of debt securities by major security type is as follows: (in millions) Amortized Gross Gross Fair December 31, 2024 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,600 $ 1 $ (274) $ 4,327 State and municipal obligations 7,357 2 (375) 6,984 Corporate obligations 24,391 56 (1,140) 23,307 U.S. agency mortgage-backed securities 10,577 1 (994) 9,584 Non-U.S. agency mortgage-backed securities 2,890 2 (175) 2,717 Total debt securities - available-for-sale 49,815 62 (2,958) 46,919 Debt securities - held-to-maturity: U.S. government and agency obligations 444 — (2) 442 State and municipal obligations 28 — (2) 26 Corporate obligations 40 — — 40 Total debt securities - held-to-maturity 512 — (4) 508 Total debt securities $ 50,327 $ 62 $ (2,962) $ 47,427 December 31, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,674 $ 3 $ (234) $ 4,443 State and municipal obligations 7,636 39 (322) 7,353 Corporate obligations 23,136 67 (1,186) 22,017 U.S. agency mortgage-backed securities 8,982 22 (708) 8,296 Non-U.S. agency mortgage-backed securities 3,023 3 (240) 2,786 Total debt securities - available-for-sale 47,451 134 (2,690) 44,895 Debt securities - held-to-maturity: U.S. government and agency obligations 506 1 (6) 501 State and municipal obligations 28 — (2) 26 Corporate obligations 69 — — 69 Total debt securities - held-to-maturity 603 1 (8) 596 Total debt securities $ 48,054 $ 135 $ (2,698) $ 45,491 Nearly all of the Company’s investments in mortgage-backed securities were rated “Double A” or better as of December 31, 2024. The Company held $4.9 billion of equity securities as of December 31, 2024 and 2023. The Company’s investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company’s investments included $3.8 billion and $1.4 billion of equity method investments primarily in operating businesses in the health care sector, as of December 31, 2024 and 2023, respectively. The allowance for credit losses on held-to-maturity securities as of December 31, 2024 and 2023 was not material. The amortized cost and fair value of debt securities as of December 31, 2024, by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Fair Amortized Fair Due in one year or less $ 3,952 $ 3,932 $ 320 $ 319 Due after one year through five years 14,845 14,384 161 161 Due after five years through ten years 12,110 11,213 14 13 Due after ten years 5,441 5,089 17 15 U.S. agency mortgage-backed securities 10,577 9,584 — — Non-U.S. agency mortgage-backed securities 2,890 2,717 — — Total debt securities $ 49,815 $ 46,919 $ 512 $ 508 The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Gross Fair Gross Fair Gross December 31, 2024 U.S. government and agency obligations $ 1,475 $ (51) $ 2,152 $ (223) $ 3,627 $ (274) State and municipal obligations 2,593 (58) 4,085 (317) 6,678 (375) Corporate obligations 7,402 (213) 11,449 (927) 18,851 (1,140) U.S. agency mortgage-backed securities 4,791 (191) 4,674 (803) 9,465 (994) Non-U.S. agency mortgage-backed securities 416 (5) 1,863 (170) 2,279 (175) Total debt securities - available-for-sale $ 16,677 $ (518) $ 24,223 $ (2,440) $ 40,900 $ (2,958) December 31, 2023 U.S. government and agency obligations $ 1,270 $ (7) $ 2,077 $ (227) $ 3,347 $ (234) State and municipal obligations 907 (7) 4,063 (315) 4,970 (322) Corporate obligations 1,826 (17) 14,696 (1,169) 16,522 (1,186) U.S. agency mortgage-backed securities 1,337 (12) 5,069 (696) 6,406 (708) Non-U.S. agency mortgage-backed securities 279 (6) 2,202 (234) 2,481 (240) Total debt securities - available-for-sale $ 5,619 $ (49) $ 28,107 $ (2,641) $ 33,726 $ (2,690) The Company’s unrealized losses from all securities as of December 31, 2024 were generated from approximately 34,000 positions out of a total of 43,000 positions. The Company believes it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectibility of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of December 31, 2024, the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities as of December 31, 2024 and 2023 was not material.

Fair Value (Notes)

Fair Value (Notes)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value [Text Block]	Fair Value Certain assets and liabilities are measured at fair value in the Consolidated Financial Statements or have fair values disclosed in the Notes to the Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety based on the lowest level input which is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The fair value hierarchy is summarized as follows: Level 1 — Quoted prices (unadjusted) for identical assets/liabilities in active markets. Level 2 — Other observable inputs, either directly or indirectly, including: • Quoted prices for similar assets/liabilities in active markets; • Quoted prices for identical or similar assets/liabilities in inactive markets (e.g., few transactions, limited information, noncurrent prices, high variability over time); • Inputs other than quoted prices observable for the asset/liability (e.g., interest rates, yield curves, implied volatilities, credit spreads); and • Inputs corroborated by other observable market data. Level 3 — Unobservable inputs cannot be corroborated by observable market data. There were no transfers in or out of Level 3 financial assets or liabilities during the years ended December 31, 2024 or 2023. Nonfinancial assets and liabilities or financial assets and liabilities measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. For the years ended December 31, 2024, 2023 and 2022, the Company recognized $710 million, $276 million and $211 million respectively, of unrealized gains in investment and other income related to fair value adjustments on equity securities primarily in the Company’s venture portfolio, based upon transactions of the same or similar security. The assets and liabilities within our South American operations held for sale as of December 31, 2024 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no other significant fair value adjustments for these assets and liabilities recorded during the years ended December 31, 2024, 2023 or 2022. The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the tables below: Cash and Cash Equivalents. The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. Fair values of cash equivalent instruments which do not trade on a regular basis in active markets are classified as Level 2. Debt and Equity Securities. Fair values of debt securities and equity securities reported at fair value on a recurring basis are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (pricing service), which generally uses quoted or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, and, if necessary, makes adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs currently observable in the markets for similar securities. Inputs often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and nonbinding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to prices reported by a secondary pricing source, such as its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company’s internal price verification procedures and reviews of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment to the prices obtained from the pricing service. Fair values of debt securities which do not trade on a regular basis in active markets but are priced using other observable inputs are classified as Level 2. Fair value estimates for Level 1 and Level 2 equity securities reported at fair value on a recurring basis are based on quoted market prices for actively traded equity securities and/or other market data for the same or comparable instruments and transactions in establishing the prices. The fair values of Level 3 investments in corporate bonds, which are not a significant portion of our investments, are estimated using valuation techniques relying heavily on management assumptions and qualitative observations. Throughout the procedures discussed above in relation to the Company’s processes for validating third-party pricing information, the Company validates the understanding of assumptions and inputs used in security pricing and determines the proper classification in the hierarchy based on such understanding. Long-Term Debt. The fair values of the Company’s long-term debt are estimated and classified using the same methodologies as the Company’s investments in debt securities. The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total December 31, 2024 Cash and cash equivalents $ 25,248 $ 64 $ — $ 25,312 Debt securities - available-for-sale: U.S. government and agency obligations 4,194 133 — 4,327 State and municipal obligations — 6,984 — 6,984 Corporate obligations 29 22,841 437 23,307 U.S. agency mortgage-backed securities — 9,584 — 9,584 Non-U.S. agency mortgage-backed securities — 2,717 — 2,717 Total debt securities - available-for-sale 4,223 42,259 437 46,919 Equity securities 1,859 24 65 1,948 Total assets at fair value $ 31,330 $ 42,347 $ 502 $ 74,179 Percentage of total assets at fair value 42 % 57 % 1 % 100 % December 31, 2023 Cash and cash equivalents $ 25,345 $ 82 $ — $ 25,427 Debt securities - available-for-sale: U.S. government and agency obligations 4,167 276 — 4,443 State and municipal obligations — 7,353 — 7,353 Corporate obligations 15 21,800 202 22,017 U.S. agency mortgage-backed securities — 8,296 — 8,296 Non-U.S. agency mortgage-backed securities — 2,786 — 2,786 Total debt securities - available-for-sale 4,182 40,511 202 44,895 Equity securities 2,468 16 69 2,553 Assets under management 1,505 2,140 110 3,755 Total assets at fair value $ 33,500 $ 42,749 $ 381 $ 76,630 Percentage of total assets at fair value 44 % 55 % 1 % 100 % The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total Total Carrying Value December 31, 2024 Debt securities - held-to-maturity $ 482 $ 26 $ — $ 508 $ 512 Long-term debt and other financing obligations $ — $ 70,565 $ — $ 70,565 $ 75,604 December 31, 2023 Debt securities - held-to-maturity $ 524 $ 72 $ — $ 596 $ 603 Long-term debt and other financing obligations $ — $ 59,851 $ — $ 59,851 $ 61,449

Property, Plant, and Capitalize

Property, Plant, and Capitalized Software (Notes)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment Disclosure [Text Block]	Property, Equipment and Capitalized Software A summary of property, equipment and capitalized software is as follows: (in millions) December 31, 2024 December 31, 2023 Land and improvements $ 364 $ 712 Buildings and improvements 4,215 5,573 Computer equipment 2,267 2,007 Furniture and fixtures 1,694 2,375 Less accumulated depreciation (3,645) (4,210) Property and equipment, net 4,895 6,457 Capitalized software 8,984 7,822 Less accumulated amortization (3,326) (2,829) Capitalized software, net 5,658 4,993 Total property, equipment and capitalized software, net $ 10,553 $ 11,450

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Notes)	12 Months Ended
	Dec. 31, 2024
Goodwill [Line Items]
Goodwill Disclosure [Text Block]	Goodwill and Other Intangible Assets Changes in the carrying amount of goodwill, by reportable segment, were as follows: (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Consolidated Balance at January 1, 2023 $ 27,395 $ 29,238 $ 17,244 $ 19,475 $ 93,352 Acquisitions 296 8,023 1,802 — 10,121 Foreign currency effects and other adjustments, net 187 (182) 261 (7) 259 Balance at December 31, 2023 27,878 37,079 19,307 19,468 103,732 Acquisitions — 2,071 — 2,305 4,376 Dispositions, foreign currency effects and other adjustments, net (717) (324) (327) (6) (1,374) Balance at December 31, 2024 $ 27,161 $ 38,826 $ 18,980 $ 21,767 $ 106,734 The gross carrying value, accumulated amortization and net carrying value of other intangible assets were as follows: December 31, 2024 December 31, 2023 (in millions) Gross Carrying Value Accumulated Amortization Net Carrying Value Gross Carrying Value Accumulated Amortization Net Carrying Value Customer-related $ 17,190 $ (6,675) $ 10,515 $ 16,636 $ (5,909) $ 10,727 Trademarks and technology 2,917 (1,284) 1,633 2,508 (958) 1,550 Trade names, trademarks, operating licenses and certificates and other indefinite-lived 10,454 — 10,454 2,116 — 2,116 Other 1,057 (391) 666 1,213 (412) 801 Total $ 31,618 $ (8,350) $ 23,268 $ 22,473 $ (7,279) $ 15,194 The fair values and weighted-average useful lives assigned to intangible assets as a result of transactions completed during years ended: 2024 2023 (in millions, except years) Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Customer-related $ 1,258 12 years $ 477 12 years Trademarks and technology 527 6 years 226 5 years Other 22 8 years 44 9 years Total finite-lived $ 1,807 10 years $ 747 9 years Total indefinite-lived - trade names, trademarks, operating licenses and certificates and other 8,795 1,427 Total intangible assets $ 10,602 $ 2,174 Estimated full year amortization expense relating to intangible assets for each of the next five years ending December 31 is as follows: (in millions) 2025 $ 1,655 2026 1,503 2027 1,424 2028 1,344 2029 1,211

Medical Costs Payable (Notes)

Medical Costs Payable (Notes)	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
Medical Costs Payable	Medical Costs Payable The following table shows the components of the change in medical costs payable for the years ended December 31: (in millions) 2024 2023 2022 Medical costs payable, beginning of period $ 32,395 $ 29,056 $ 24,483 Acquisitions (dispositions), net (755) 1 308 Reported medical costs: Current year 264,885 242,734 211,252 Prior years (700) (840) (410) Total reported medical costs 264,185 241,894 210,842 Medical payments: Payments for current year (231,890) (211,380) (184,049) Payments for prior years (29,532) (27,176) (22,528) Total medical payments (261,422) (238,556) (206,577) Less: medical costs payable included within businesses held for sale (179) — — Medical costs payable, end of period $ 34,224 $ 32,395 $ 29,056 For the years ended December 31, 2024, 2023 and 2022, prior years’ medical cost reserve development included no individual factors that were significant. Medical costs payable included IBNR of $23.7 billion and $22.3 billion at December 31, 2024 and 2023, respectively. Substantially all of the IBNR balance as of December 31, 2024 relates to the current year. The following is information about incurred and paid medical cost development as of December 31, 2024: Net Incurred Medical Costs (in millions) For the Years Ended December 31, Year 2023 2024 2023 $ 242,734 $ 242,156 2024 264,885 Total $ 507,041 Net Cumulative Medical Payments (in millions) For the Years Ended December 31, Year 2023 2024 2023 $ (211,380) $ (240,112) 2024 (231,890) Total (472,002) Net remaining outstanding liabilities prior to 2023 119 Acquisitions (dispositions), net (755) Medical costs payable included within businesses held for sale (179) Total medical costs payable $ 34,224

Short-Term Borrowings and Long-

Short-Term Borrowings and Long-Term Debt (Notes)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Short-Term Borrowings and Long-Term Debt [Text Block]	Short-Term Borrowings and Long-Term Debt Short-term borrowings and senior unsecured long-term debt consisted of commercial paper and notes as follows: Carrying Value as of December 31, Carrying Value as of December 31, (in millions, except percentages) 2024 2023 (continued) 2024 2023 Commercial paper $ 1,300 $ 1,088 $1,000 4.625%, Jul 2035 971 1,014 $750 3.5%, Feb 2024 — 750 $850 5.8%, Mar 2036 838 838 $1,000 0.55%, May 2024 — 999 $500 6.5%, Jun 2037 492 491 $750 2.375%, Aug 2024 — 750 $650 6.625%, Nov 2037 641 640 $500 5%, Oct 2024 — 499 $1,100 6.875%, Feb 2038 1,079 1,078 $2,000 3.75%, Jul 2025 1,999 1,997 $1,250 3.5%, Aug 2039 1,243 1,242 $750 5.15%, Oct 2025 749 748 $1,000 2.75%, May 2040 970 968 $300 3.7%, Dec 2025 300 299 $300 5.7%, Oct 2040 296 296 $500 1.25%, Jan 2026 499 498 $350 5.95%, Feb 2041 346 346 $1,000 3.1%, Mar 2026 999 998 $1,500 3.05%, May 2041 1,485 1,484 $1,000 1.15%, May 2026 953 924 $600 4.625%, Nov 2041 590 590 $500 floating rate, Jul 2026 499 — $502 4.375%, Mar 2042 487 486 $650 4.75%, Jul 2026 648 — $625 3.95%, Oct 2042 610 609 $750 3.45%, Jan 2027 749 748 $750 4.25%, Mar 2043 737 736 $500 4.6%, Apr 2027 496 — $1,500 5.5%, Jul 2044 1,475 — $625 3.375%, Apr 2027 623 622 $2,000 4.75%, Jul 2045 1,976 1,975 $600 3.7%, May 2027 598 598 $750 4.2%, Jan 2047 739 739 $950 2.95%, Oct 2027 946 944 $725 4.25%, Apr 2047 718 718 $1,000 5.25%, Feb 2028 998 1,011 $950 3.75%, Oct 2047 935 935 $1,150 3.85%, Jun 2028 1,147 1,146 $1,350 4.25%, Jun 2048 1,332 1,331 $850 3.875%, Dec 2028 847 846 $1,100 4.45%, Dec 2048 1,087 1,087 $1,250 4.25%, Jan 2029 1,221 1,238 $1,250 3.7%, Aug 2049 1,237 1,236 $400 4.7%, Apr 2029 398 — $1,250 2.9%, May 2050 1,212 1,211 $900 4%, May 2029 854 862 $2,000 3.25%, May 2051 1,972 1,972 $1,000 2.875%, Aug 2029 902 908 $2,000 4.75%, May 2052 1,966 1,966 $1,250 4.8%, Jan 2030 1,225 — $2,000 5.875%, Feb 2053 1,968 1,968 $1,250 5.3%, Feb 2030 1,243 1,275 $2,000 5.05%, Apr 2053 1,969 1,969 $1,250 2%, May 2030 1,240 1,238 $1,750 5.375%, Apr 2054 1,729 — $1,000 4.9%, Apr 2031 982 — $2,750 5.625%, Jul 2054 2,724 — $1,500 2.3%, May 2031 1,271 1,290 $1,250 3.875%, Aug 2059 1,229 1,229 $1,500 4.95%, Jan 2032 1,489 — $1,000 3.125%, May 2060 967 966 $1,500 4.2%, May 2032 1,372 1,412 $1,000 4.95%, May 2062 981 981 $2,000 5.35%, Feb 2033 1,966 2,046 $1,500 6.05%, Feb 2063 1,466 1,466 $1,500 4.5%, Apr 2033 1,410 1,463 $1,750 5.2%, Apr 2063 1,710 1,709 $1,250 5%, Apr 2034 1,214 — $1,100 5.5%, Apr 2064 1,085 — $2,000 5.15%, Jul 2034 1,959 — $1,850 5.75%, Jul 2064 1,822 — Total short-term borrowings and long-term debt $ 76,180 $ 61,473 The Company’s long-term debt obligations also included $0.7 billion and $1.1 billion of other financing obligations, of which $197 million and $188 million were current as of December 31, 2024 and 2023, respectively. Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2025 $ 4,548 2026 3,756 2027 3,531 2028 3,106 2029 3,656 Thereafter 59,908 Short-Term Borrowings Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of December 31, 2024, the Company’s outstanding commercial paper had a weighted-average annual interest rate of 4.4%. The Company has $7.0 billion five three Debt Covenants As of December 31, 2024, the Company was in compliance with the various covenants under its bank credit facilities.

Income Taxes (Notes)

Income Taxes (Notes)	12 Months Ended
	Dec. 31, 2024
Income Tax Examination [Line Items]
Income Tax Disclosure [Text Block]	Income Taxes The current income tax provision reflects the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported. The deferred income tax provision or benefit generally reflects the net change in deferred income tax assets and liabilities during the year, excluding any deferred income tax assets and liabilities of acquired businesses. The components of income before income taxes, based upon tax jurisdiction, for the years ended December 31 are as follows: (in millions) 2024 2023 2022 Income before income taxes: Domestic $ 28,264 $ 29,210 $ 26,685 Foreign (8,193) (98) (342) Total income before income taxes $ 20,071 $ 29,112 $ 26,343 The components of the provision for income taxes for the years ended December 31 are as follows: (in millions) 2024 2023 2022 Current Provision: Federal $ 3,453 $ 4,418 $ 4,842 State and local 416 716 855 Foreign 1,256 1,079 680 Total current provision 5,125 6,213 6,377 Deferred benefit (296) (245) (673) Total provision for income taxes $ 4,829 $ 5,968 $ 5,704 The reconciliation of the tax provision at the U.S. federal statutory rate to the provision for income taxes and the effective tax rate for the years ended December 31 is as follows: (in millions, except percentages) 2024 2023 2022 Tax provision at the U.S. federal statutory rate $ 4,215 21.0 % $ 6,114 21.0 % $ 5,532 21.0 % State income taxes, net of federal benefit 343 1.7 567 2.0 621 2.4 Share-based awards - excess tax benefit (96) (0.5) (75) (0.3) (110) (0.4) Non-deductible compensation 171 0.9 174 0.6 150 0.6 Foreign rate differential (369) (1.8) (442) (1.5) (265) (1.0) Tax effect of dispositions and other strategic transactions 1,215 6.1 (29) (0.1) (215) (0.8) Other, net (650) (3.3) (341) (1.2) (9) (0.1) Provision for income taxes $ 4,829 24.1 % $ 5,968 20.5 % $ 5,704 21.7 % Deferred income tax assets and liabilities are recognized for the differences between the financial and income tax reporting bases of assets and liabilities based on enacted tax rates and laws. The components of deferred income tax assets and liabilities as of December 31 are as follows: (in millions) 2024 2023 Deferred income tax assets: Accrued expenses and allowances $ 1,055 $ 754 U.S. federal and state net operating loss carryforwards 442 417 Share-based compensation 189 173 Nondeductible liabilities 343 329 Non-U.S. tax loss carryforwards 21 1,061 Lease liability 846 930 Net unrealized losses on investments 669 586 Other-domestic 597 327 Other-non-U.S. 59 484 Subtotal 4,221 5,061 Less: valuation allowances (397) (366) Total deferred income tax assets 3,824 4,695 Deferred income tax liabilities: U.S. federal and state intangible assets (4,479) (3,712) Non-U.S. goodwill and intangible assets (82) (731) Capitalized software (288) (415) Depreciation and amortization (400) (371) Prepaid expenses (374) (326) Outside basis in partnerships (960) (811) Lease right-of-use asset (833) (914) Other-non-U.S. (28) (436) Total deferred income tax liabilities (7,444) (7,716) Net deferred income tax liabilities $ (3,620) $ (3,021) Valuation allowances are provided when it is considered more likely than not deferred tax assets will not be realized. The valuation allowances primarily relate to future tax benefits on certain federal, state and non-U.S. net operating loss carryforwards. Substantially all of the federal net operating loss carryforwards have indefinite carryforward periods; state net operating loss carryforwards expire beginning in 2025 through 2044, with some having an indefinite carryforward period. Additionally, as of December 31, 2024, the Company has historical non-U.S. net operating loss carryforwards for which a deferred tax asset and valuation allowance of $4.1 billion are not established because realization of the loss carryforwards is remote. As of December 31, 2024, except for subsidiaries held for sale, the Company’s undistributed earnings from non-U.S. subsidiaries are intended to be indefinitely reinvested in non-U.S. operations, and therefore no U.S. deferred taxes have been recorded. Taxes payable on the remittance of such earnings would be minimal. A reconciliation of the beginning and ending amount of unrecognized tax benefits as of December 31 is as follows: (in millions) 2024 2023 2022 Gross unrecognized tax benefits, beginning of period $ 3,716 $ 3,081 $ 2,310 Gross increases: Current year tax positions 578 782 586 Prior year tax positions 10 97 206 Gross decreases: Prior year tax positions (121) (212) (21) Statute of limitations lapses and settlements (60) (32) — Gross unrecognized tax benefits, end of period $ 4,123 $ 3,716 $ 3,081 The Company believes it is reasonably possible its liability for unrecognized tax benefits will decrease in the next twelve months by $101 million as a result of audit settlements and the expiration of statutes of limitations. The Company classifies net interest and penalties associated with uncertain income tax positions as income taxes within its Consolidated Statements of Operations. During the years ended December 31, 2024, 2023 and 2022, the Company recognized $210 million, $177 million and $64 million of net interest and penalties, respectively. The Company had $637 million and $430 million of accrued interest and penalties for uncertain tax positions as of December 31, 2024 and 2023, respectively. These amounts are not included in the reconciliation above. As of December 31, 2024, there were $2.0 billion of unrecognized tax benefits which, if recognized, would affect the effective tax rate. The Company currently files income tax returns in the United States, various states and localities and non-U.S. jurisdictions. The U.S. Internal Revenue Service (IRS) has completed exams on the consolidated income tax returns for fiscal years 2016 and prior. The Company’s 2017 through 2020 tax years are under review by the IRS under its Compliance Assurance Program. The Company is no longer subject to state income tax examinations prior to the 2015 tax year. The Company is subject to examination in non-U.S. jurisdictions for years 2015 and forward.

Shareholders' Equity (Notes)

Shareholders' Equity (Notes)	12 Months Ended
	Dec. 31, 2024
Shareholders' Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Shareholders' Equity Regulatory Capital and Dividend Restrictions The Company’s regulated insurance and HMO subsidiaries are subject to regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital, as defined by each jurisdiction, and restrict the timing and amount of dividends and other distributions which may be paid to their parent companies. In the United States, most of these state regulations and standards are generally consistent with model regulations established by the NAIC. These standards generally permit dividends to be paid from statutory unassigned surplus of the regulated subsidiary and are limited based on the regulated subsidiary’s level of statutory net income and statutory capital and surplus. These dividends are referred to as “ordinary dividends” and generally may be paid without prior regulatory approval. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an “extraordinary dividend” and must receive prior regulatory approval. For the year ended December 31, 2024, the Company’s domestic insurance and HMO subsidiaries paid their parent companies dividends of $9.2 billion, including $2.6 billion of extraordinary dividends. For the year ended December 31, 2023, the Company’s domestic insurance and HMO subsidiaries paid their parent companies dividends of $8.0 billion, including $4.9 billion of extraordinary dividends. The Company's financially regulated subsidiaries had estimated aggregate statutory capital and surplus of $37.8 billion as of December 31, 2024. The estimated statutory capital and surplus necessary to satisfy regulatory requirements of the Company's financially regulated subsidiaries was approximately $20.4 billion as of December 31, 2024. Optum Bank must meet minimum capital requirements of the FDIC under the capital adequacy rules to which it is subject. At December 31, 2024, the Company believes Optum Bank met the FDIC requirements to be considered “Well Capitalized.” Share Repurchase Program Under its Board of Directors’ authorization, the Company maintains a share repurchase program. The objectives of the share repurchase program are to optimize the Company’s capital structure and cost of capital, thereby improving returns to shareholders, as well as to offset the dilutive impact of share-based awards. Repurchases may be made from time to time in open market purchases or other types of transactions (including prepaid or structured share repurchase programs), subject to certain restrictions. In June 2024, the Board of Directors amended the Company’s share repurchase program to authorize the repurchase of up to 35 million shares of its common stock, in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program. A summary of common share repurchases for the years ended December 31, 2024 and 2023 is as follows: Years Ended December 31, (in millions, except per share data) 2024 2023 Common share repurchases, shares 17 16 Common share repurchases, average price per share $ 529.85 $ 493.79 Common share repurchases, aggregate cost $ 8,942 $ 8,000 Board authorized shares remaining 33 15 Dividends In June 2024, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $8.40 compared to $7.52 per share, which the Company had paid since June 2023. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change. The following table provides details of the Company’s 2024 dividend payments: Payment Date Amount per Share Total Amount Paid (in millions) March 19 $ 1.88 $ 1,729 June 25 2.10 1,935 September 24 2.10 1,937 December 17 2.10 1,932

Share-Based Compensation (Notes

Share-Based Compensation (Notes)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Share-based Payment Arrangement [Text Block]	Share-Based Compensation The Company’s outstanding share-based awards consist mainly of non-qualified stock options and restricted shares. As of December 31, 2024, the Company had 48 million shares available for future grants of share-based awards under the 2020 Stock Incentive Plan. As of December 31, 2024, there were 16 million shares of common stock available for issuance under the ESPP. Stock Options Stock option activity for the year ended December 31, 2024 is summarized in the table below: Shares Weighted- Weighted- Aggregate (in millions) (in years) (in millions) Outstanding at beginning of period 21 $ 320 Granted 3 522 Exercised (6) 253 Forfeited (1) 480 Outstanding at end of period 17 370 5.6 $ 2,338 Exercisable at end of period 10 298 4.2 2,115 Vested and expected to vest, end of period 17 368 5.5 2,335 Restricted Shares Restricted share activity for the year ended December 31, 2024 is summarized in the table below: (shares in millions) Shares Weighted-Average Nonvested at beginning of period 4 $ 449 Granted 2 523 Vested (2) 435 Nonvested at end of period 4 489 Other Share-Based Compensation Data (in millions, except per share amounts) For the Years Ended December 31, 2024 2023 2022 Stock Options Weighted-average grant date fair value of shares granted, per share $ 138 $ 134 $ 116 Total intrinsic value of stock options exercised 1,886 1,325 1,419 Restricted Shares Weighted-average grant date fair value of shares granted, per share 523 493 483 Total fair value of restricted shares vested 690 803 760 Employee Stock Purchase Plan Number of shares purchased 1 1 1 Share-Based Compensation Items Share-based compensation expense, before tax $ 1,018 $ 1,059 $ 925 Share-based compensation expense, net of tax effects 896 937 836 Income tax benefit realized from share-based award exercises 216 231 207 (in millions, except years) December 31, 2024 Unrecognized compensation expense related to share awards $ 1,099 Weighted-average years to recognize compensation expense 1.3 Share-Based Compensation Recognition and Estimates The principal assumptions the Company used in calculating grant-date fair value for stock options were as follows: For the Years Ended December 31, 2024 2023 2022 Risk-free interest rate 3.6% - 4.4% 3.8% - 4.6% 1.9% - 4.3% Expected volatility 25.5% - 30.7% 29.7% - 30.6% 30.6% - 30.8% Expected dividend yield 1.4% - 1.5% 1.3% - 1.5% 1.2% Forfeiture rate 5.0% 5.0% 5.0% Expected life in years 4.6 4.6 4.7 Risk-free interest rates are based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on the historical volatility of the Company’s common stock and the implied volatility from exchange-traded options on the Company’s common stock. Expected dividend yields are based on the per share cash dividend paid by the Company. The Company uses historical data to estimate option exercises and forfeitures within the valuation model. The expected lives of options granted represent the periods of time the awards granted are expected to be outstanding based on historical exercise patterns. Other Employee Benefit Plans The Company offers a 401(k) plan for its employees. Compensation expense related to this plan was not material for the years ended December 31, 2024, 2023 and 2022. In addition, the Company maintains non-qualified, deferred compensation plans, which allow certain members of senior management and executives to defer portions of their salary or bonus. The deferrals are recorded within long-term investments with an approximately equal amount in other liabilities in the Consolidated Balance Sheets. The total deferrals are distributable based upon termination of employment or other periods, as elected under each plan and were $2.1 billion and $1.9 billion as of December 31, 2024 and 2023, respectively.

Commitments and Contingencies (

Commitments and Contingencies (Notes)	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Leases Operating lease costs, including immaterial variable and short-term lease costs, were $1.4 billion, $1.4 billion and $1.3 billion for the years ended December 31, 2024, 2023 and 2022, respectively. Cash payments made on the Company’s operating lease liabilities were $1.1 billion, $1.1 billion and $1.0 billion for the years ended December 31, 2024, 2023 and 2022, respectively, which were classified within operating activities in the Consolidated Statements of Cash Flows. As of December 31, 2024, the Company’s weighted-average remaining lease term and weighted-average discount rate for its operating leases were 9.5 years and 4.7%, respectively. As of December 31, 2024, future minimum annual lease payments under all non-cancelable operating leases were as follows: (in millions) Future Minimum Lease Payments 2025 $ 1,014 2026 876 2027 688 2028 568 2029 583 Thereafter 2,465 Total future minimum lease payments 6,194 Less imputed interest (1,305) Total $ 4,889 Other Commitments The Company provides guarantees related to its service level under certain contracts. If minimum standards are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. None of the amounts accrued, paid or charged to income for service level guarantees were material as of December 31, 2024, 2023 or 2022. Pending Acquisitions As of December 31, 2024, the Company has entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $4 billion. Legal Matters The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices. The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred. Government Investigations, Audits and Reviews The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the IRS, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the FDIC, the Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and reviews by applicable foreign governments and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans. On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.

Dispositions and Held for Sale

Dispositions and Held for Sale (Notes)	12 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Dispositions and Held for Sale [Text Block]	Dispositions and Held for Sale During the year ended December 31, 2024, the Company completed or initiated various business portfolio refinement and asset disposition activities. The Company recorded a loss of $7.1 billion related to the sale of its Brazil operations, of which $4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss, and a loss of $1.2 billion related to the reclassification of the Company’s remaining South American operations as held for sale, of which $855 million related to the impact of cumulative foreign currency translation losses. As these losses relate to our strategic exit of South American markets and include significant losses related to foreign currency translation effects, these losses are included within loss on sale of subsidiary and subsidiaries held for sale on the Consolidated Statement of Operations. The sales of the Company’s remaining South American assets are expected to close within a year, subject to regulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid and other current assets and other current liabilities on the Consolidated Balance Sheet, respectively. The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of December 31, 2024, respectively, were as follows: (in millions) Brazil Businesses Assets Cash and cash equivalents $ 778 $ 219 Accounts receivable and other current assets 515 573 Long-term investments 788 41 Property, equipment and capitalized software 1,052 641 Deferred tax assets 1,035 — Goodwill and other intangible assets 317 413 Other long-term assets 439 231 Remeasurement of assets of businesses held for sale to fair value less cost to sell (1) — (1,224) Total assets $ 4,924 $ 894 Liabilities Medical costs payable $ 701 $ 179 Accounts payable and other current liabilities 834 338 Other long-term liabilities 136 504 Total liabilities $ 1,671 $ 1,021 (1) Includes the effect of $855 million of cumulative foreign currency translation losses and $56 million of noncontrolling interests. As a result of continued portfolio refinement, the Company sold other businesses and assets and entered into strategic transactions. These transactions resulted in total consideration received of $3.0 billion and an additional $1.9 billion of equity method investments related to the valuation of our retained interests in certain transactions. The carrying value for these transactions was $1.0 billion, primarily related to goodwill. The gains from business portfolio refinement, including strategic transactions, were recorded within operating costs in the Consolidated Statement of Operations and contributed about 80 basis points ($3.3 billion) to the operating cost ratio, nearly half ($1.4 billion) related to Optum Health with the remainder split between UnitedHealthcare ($1.1 billion) and Optum Insight ($800 million). Certain transactions also included various put and call options, which were valued at $630 million and included in other liabilities on the Consolidated Balance Sheet. As of December 31, 2024 the total estimated future obligation under these arrangements if the Company decided or was required to repurchase these interests was up to $3.4 billion.

Segment Financial Information (

Segment Financial Information (Notes)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Financial Information [Text Block]	Segment Financial Information Factors used to determine the Company’s reportable segments include the nature of operating activities, economic characteristics, existence of separate senior management teams and the type of information used by the Company’s chief operating decision maker (CODM), which is the Chief Executive Officer, to evaluate its results of operations. Reportable segments with similar economic characteristics, products and services, customers, distribution methods and operational processes which operate in a similar regulatory environment are combined. The CODM uses consolidated expense information and segment earnings from operations to assess performance and determine allocation of resources. The following is a description of the types of products and services from which each of the Company’s four reportable segments derives its revenues: • UnitedHealthcare includes the combined results of operations of UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. The businesses share significant common assets, including a contracted network of physicians, health care professionals, hospitals and other facilities, information technology and consumer engagement infrastructure and other resources. UnitedHealthcare Employer & Individual offers an array of consumer-oriented health benefit plans and services for employers and individuals. UnitedHealthcare Medicare & Retirement provides health care coverage and health and well-being services to individuals age 50 and older, addressing their unique needs. UnitedHealthcare Community & State provides diversified health care benefits products and services to state programs caring for the economically disadvantaged, the medically underserved and those without the benefit of employer-funded health care coverage. • Optum Health focuses on care delivery, including value-based care; care management; wellness and consumer engagement and health financial services. Optum Health is building a comprehensive, connected health care delivery and engagement platform by directly providing high-quality care, helping people manage chronic and complex health needs, and proactively engaging consumers in managing their health through in-person, in-home, virtual and digital clinical platforms. • Optum Insight brings together advanced analytics, technology and health care expertise to deliver integrated services and solutions. Hospital systems, physicians, health plans, governments, life sciences companies and other organizations depend on Optum Insight to help them improve performance, achieve efficiency, reduce costs, meet compliance mandates and modernize their core operating systems to meet the changing needs of the health system. • Optum Rx offers pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, purchasing and clinical capabilities, and develops programs in areas such as step therapy, formulary management, drug adherence and disease and drug therapy management. Optum Rx integrates pharmacy and medical care and is positioned to serve patients with complex clinical needs and consumers looking for a better digital pharmacy experience with transparent pricing. The Company’s accounting policies for reportable segment operations are consistent with those described in the Summary of Significant Accounting Policies (see Note 2 ). Transactions between reportable segments principally consist of sales of pharmacy care products and services to UnitedHealthcare customers by Optum Rx; care delivery, care management services and certain product offerings sold to UnitedHealthcare by Optum Health; and health information and technology solutions, consulting and other services sold to UnitedHealthcare by Optum Insight. These transactions are recorded at management’s estimate of fair value. Transactions with affiliated customers are eliminated in consolidation. Assets and liabilities jointly used are assigned to each reportable segment using estimates of pro-rata usage. Cash and investments are assigned so each reportable segment has working capital and/or at least minimum specified levels of regulatory capital. As a percentage of the Company’s total consolidated revenues, premium revenues from CMS were 40%, 40% and 38% for the years ended December 31, 2024, 2023 and 2022, respectively, most of which were generated by UnitedHealthcare Medicare & Retirement and included in the UnitedHealthcare segment. U.S. customer revenue represented approximately 99%, 97% and 97% of consolidated total revenues for 2024, 2023 and 2022, respectively. Long-lived fixed assets located in the United States represented approximately 92% and 82% of the total long-lived fixed assets as of December 31, 2024 and 2023, respectively. The non-U.S. revenues and fixed assets are primarily related to UnitedHealthcare Employer & Individual’s international businesses. The following table presents the reportable segment financial information: Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated 2024 Revenues - unaffiliated customers: Premiums $ 286,004 $ 22,806 $ — $ — $ — $ 22,806 $ — $ 308,810 Products — 277 174 49,775 — 50,226 — 50,226 Services 9,791 16,153 6,466 3,630 — 26,249 — 36,040 Total revenues - unaffiliated customers 295,795 39,236 6,640 53,405 — 99,281 — 395,076 Total revenues - affiliated customers — 63,883 11,881 79,512 (4,389) 150,887 (150,887) — Investment and other income 2,413 2,239 236 314 — 2,789 — 5,202 Total revenues $ 298,208 $ 105,358 $ 18,757 $ 133,231 $ (4,389) $ 252,957 $ (150,887) $ 400,278 Total operating costs (a) $ 282,624 $ 97,588 $ 15,660 $ 127,395 $ (4,389) $ 236,254 $ (150,887) $ 367,991 Earnings from operations $ 15,584 $ 7,770 $ 3,097 $ 5,836 $ — $ 16,703 $ — $ 32,287 Interest expense — — — — — — (3,906) (3,906) Loss on sale of subsidiary and subsidiaries held for sale (8,310) — — — — — — (8,310) Earnings before income taxes $ 7,274 $ 7,770 $ 3,097 $ 5,836 $ — $ 16,703 $ (3,906) $ 20,071 Total assets $ 119,009 $ 96,472 $ 34,452 $ 59,086 $ — $ 190,010 $ (10,741) $ 298,278 Purchases of property, equipment and capitalized software 781 1,008 1,291 419 — 2,718 — 3,499 Depreciation and amortization 889 1,123 1,294 793 — 3,210 — 4,099 2023 Revenues - unaffiliated customers: Premiums $ 269,052 $ 21,775 $ — $ — $ — $ 21,775 $ — $ 290,827 Products — 207 162 42,214 — 42,583 — 42,583 Services 10,057 14,109 7,760 2,197 — 24,066 — 34,123 Total revenues - unaffiliated customers 279,109 36,091 7,922 44,411 — 88,424 — 367,533 Total revenues - affiliated customers — 57,696 10,896 71,484 (3,703) 136,373 (136,373) — Investment and other income 2,251 1,532 114 192 — 1,838 — 4,089 Total revenues $ 281,360 $ 95,319 $ 18,932 $ 116,087 $ (3,703) $ 226,635 $ (136,373) $ 371,622 Total operating costs (a) $ 264,945 $ 88,759 $ 14,664 $ 110,972 $ (3,703) $ 210,692 $ (136,373) $ 339,264 Earnings from operations $ 16,415 $ 6,560 $ 4,268 $ 5,115 $ — $ 15,943 $ — $ 32,358 Interest expense — — — — — — (3,246) (3,246) Earnings before income taxes $ 16,415 $ 6,560 $ 4,268 $ 5,115 $ — $ 15,943 $ (3,246) $ 29,112 Total assets $ 110,943 $ 89,432 $ 34,173 $ 51,266 $ — $ 174,871 $ (12,094) $ 273,720 Purchases of property, equipment and capitalized software 866 1,199 974 347 — 2,520 — 3,386 Depreciation and amortization 989 1,058 1,229 696 — 2,983 — 3,972 2022 Revenues - unaffiliated customers: Premiums $ 238,783 $ 18,374 $ — $ — $ — $ 18,374 $ — $ 257,157 Products — 72 180 37,172 — 37,424 — 37,424 Services 10,035 10,917 4,996 1,603 — 17,516 — 27,551 Total revenues - unaffiliated customers 248,818 29,363 5,176 38,775 — 73,314 — 322,132 Total revenues - affiliated customers — 40,883 9,288 60,936 (2,760) 108,347 (108,347) — Investment and other income 923 928 117 62 — 1,107 — 2,030 Total revenues $ 249,741 $ 71,174 $ 14,581 $ 99,773 $ (2,760) $ 182,768 $ (108,347) $ 324,162 Total operating costs (a) $ 235,362 $ 65,142 $ 10,993 $ 95,337 $ (2,760) $ 168,712 $ (108,347) $ 295,727 Earnings from operations $ 14,379 $ 6,032 $ 3,588 $ 4,436 $ — $ 14,056 $ — $ 28,435 Interest expense — — — — — — (2,092) (2,092) Earnings before income taxes $ 14,379 $ 6,032 $ 3,588 $ 4,436 $ — $ 14,056 $ (2,092) $ 26,343 Total assets $ 107,094 $ 68,950 $ 31,090 $ 47,476 $ — $ 147,516 $ (8,905) $ 245,705 Purchases of property, equipment and capitalized software 799 997 698 308 — 2,003 — 2,802 Depreciation and amortization 973 943 841 643 — 2,427 — 3,400 (a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each reportable segment.

Schedule I (Notes)

Schedule I (Notes)	12 Months Ended
	Dec. 31, 2024
Condensed Statement of Income Captions [Line Items]
Condensed Financial Information of Parent Company Only Disclosure [Text Block]	Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Balance Sheets (in millions, except per share data) December 31, December 31, Assets Current assets: Cash and cash equivalents $ 234 $ 776 Other current assets 411 570 Total current assets 645 1,346 Equity in net assets of subsidiaries 179,209 153,692 Long-term notes receivable from subsidiaries 6,062 5,693 Other assets 920 831 Total assets $ 186,836 $ 161,562 Liabilities and shareholders’ equity Current liabilities: Accounts payable and accrued liabilities $ 1,501 $ 1,116 Short-term notes payable to subsidiaries 2,016 9,887 Short-term borrowings and current maturities of long-term debt 4,348 4,086 Total current liabilities 7,865 15,089 Long-term debt, less current maturities 71,831 57,387 Long-term notes payable to subsidiaries 14,405 — Other liabilities 77 330 Total liabilities 94,178 72,806 Commitments and contingencies (Note 4) Shareholders’ equity: Preferred stock, $0.001 par value -10 shares authorized; no shares issued or outstanding — — Common stock, $0.01 par value - 3,000 shares authorized; 915 and 924 issued and outstanding 9 9 Retained earnings 96,036 95,774 Accumulated other comprehensive loss (3,387) (7,027) Total UnitedHealth Group shareholders’ equity 92,658 88,756 Total liabilities and shareholders’ equity $ 186,836 $ 161,562 See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Comprehensive Income For the Years Ended December 31, (in millions) 2024 2023 2022 Revenues: Investment and other income $ 368 $ 312 $ 255 Total revenues 368 312 255 Operating costs: Operating costs 108 35 121 Interest expense 4,544 3,469 2,110 Total operating costs 4,652 3,504 2,231 Loss before income taxes (4,284) (3,192) (1,976) Benefit for income taxes 1,032 654 429 Loss of parent company (3,252) (2,538) (1,547) Equity in undistributed income of subsidiaries 17,657 24,919 21,667 Net earnings 14,405 22,381 20,120 Other comprehensive income (loss) 3,640 1,366 (3,009) Comprehensive income $ 18,045 $ 23,747 $ 17,111 See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Cash Flows For the Years Ended December 31, (in millions) 2024 2023 2022 Operating activities Cash flows from operating activities $ 4,852 $ 17,443 $ 14,754 Investing activities Issuances of notes to subsidiaries (349) (41) (567) Repayments of notes to subsidiaries 225 817 281 Cash paid for acquisitions and other transactions (13,750) (8,144) (20,728) Return of capital to parent company 21 639 1,424 Capital contributions to subsidiaries — (2,472) (570) Cash received from dispositions, net 2,444 624 2,787 Other, net 30 286 — Cash flows used for investing activities (11,379) (8,291) (17,373) Financing activities Common stock repurchases (9,000) (8,000) (7,000) Proceeds from common stock issuances 1,846 1,353 1,253 Cash dividends paid (7,533) (6,761) (5,991) (Repayments of) proceeds from short-term borrowings, net (151) 11 732 Proceeds from issuance of long-term debt 17,811 6,394 14,819 Repayments of long-term debt (3,000) (2,125) (3,015) (Repayments of) proceeds from short-term notes from subsidiaries, net (7,966) 1,188 594 Proceeds from long-term notes from subsidiaries 14,396 — — Repayments of long-term notes from subsidiaries (28) — — Other, net (390) (702) (674) Cash flows from (used for) financing activities 5,985 (8,642) 718 (Decrease) increase in cash and cash equivalents (542) 510 (1,901) Cash and cash equivalents, beginning of period 776 266 2,167 Cash and cash equivalents, end of period $ 234 $ 776 $ 266 Supplemental cash flow disclosures Cash paid for interest $ 4,241 $ 3,257 $ 1,969 Cash paid for income taxes 2,450 4,426 4,298 See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Notes to Condensed Financial Statements 1. Basis of Presentation UnitedHealth Group’s parent company financial information has been derived from its consolidated financial statements and should be read in conjunction with the consolidated financial statements included in this Form 10-K. The accounting policies for the registrant are the same as those described in Note 2 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” 2. Subsidiary Transactions Investment in Subsidiaries. UnitedHealth Group’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries. Dividends and Capital Distributions. Cash dividends received from subsidiaries and included in Cash Flows from Operating Activities in the Condensed Statements of Cash Flows were $19.3 billion, $18.5 billion and $15.6 billion in 2024, 2023 and 2022, respectively. Additionally, $21 million, $639 million and $1.4 billion in cash were received as a return of capital to the parent company during 2024, 2023 and 2022, respectively. 3. Short-Term Borrowings and Long-Term Debt Discussion of short-term borrowings and long-term debt can be found in Note 8 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” Long-term debt obligations of the parent company do not include other financing obligations at subsidiaries which totaled $0.7 billion and $1.1 billion at December 31, 2024 and 2023. Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2025 $ 4,350 2026 3,650 2027 3,425 2028 3,000 2029 3,550 Thereafter 59,802 UnitedHealth Group’s parent company had short-term notes payable to subsidiaries of $2.0 billion and $9.9 billion as of December 31, 2024 and 2023, respectively, which included on-demand features. UnitedHealth Group’s parent company had long-term notes payable to subsidiaries of $14.4 billion as of December 31, 2024. 4. Commitments and Contingencies Certain subsidiaries are guaranteed by UnitedHealth Group’s parent company in the event of insolvency. UnitedHealth Group’s parent company also provides guarantees related to its service level under certain contracts. None of the amounts accrued, paid or charged to income for service level guarantees were material as of December 31, 2024, 2023 or 2022. For a summary of commitments and contingencies, see Note 12 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net earnings	$ 14,405	$ 22,381	$ 20,120

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	The Company’s framework includes an incident management and response program that continuously monitors the Company’s information systems for vulnerabilities, threats and incidents; manages and takes action to contain incidents that occur; remediates vulnerabilities; and communicates the details of significant threats and incidents to management, including the Chief Digital and Technology Officer and the Chief Security Officer, as deemed necessary or appropriate. Pursuant to the Company’s incident response plan, incidents are reported to the Audit and Finance Committee and appropriate government agencies and other authorities, as deemed necessary or appropriate, considering the actual or potential impact, significance and scope. We require our third-party partners and contractors to handle data in accordance with our data privacy and information security requirements and applicable laws. We regularly engage with our suppliers, partners, contractors, service providers and internal development teams to identify and remediate vulnerabilities in a timely manner and monitor system upgrades to mitigate future risk, and evaluate whether they employ appropriate and effective controls and continuity plans for their systems and operations. To ensure that our program is designed and operating effectively, our infrastructure and information systems are audited periodically by internal and external auditors. We have obtained various certifications from industry-recognized certifying organizations as a result of certain external audits. We also perform regular vulnerability assessments and penetration tests to improve system security and address emerging security threats. Our internal audit team independently assesses security controls against our enterprise policies to evaluate compliance and leverages a combination of auditing and security frameworks to evaluate how leading practices are applied throughout our enterprise. Audit results and remediation progress are reported to and monitored by senior management and the Audit and Finance Committee. We also periodically partner with industry-leading cybersecurity firms to assess our cybersecurity program. These assessments complement our other assessment work by evaluating our cybersecurity program as a whole. We complete an enterprise information risk assessment as part of our overall enterprise information security risk management assessment, which is overseen by our Chief Security Officer. This risk assessment is a review of internal and external threats that evaluates changes to the information risk landscape to inform the investments and program enhancements to be made in the future to rapidly respond and recover from potential attacks, including rebuild and recovery protocols for key systems. We evaluate our enterprise information security risk to address unexpected or unforeseen changes in the risk environment or our systems and the resulting impacts are communicated to the Company’s overall enterprise risk management program.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We complete an enterprise information risk assessment as part of our overall enterprise information security risk management assessment, which is overseen by our Chief Security Officer. This risk assessment is a review of internal and external threats that evaluates changes to the information risk landscape to inform the investments and program enhancements to be made in the future to rapidly respond and recover from potential attacks, including rebuild and recovery protocols for key systems. We evaluate our enterprise information security risk to address unexpected or unforeseen changes in the risk environment or our systems and the resulting impacts are communicated to the Company’s overall enterprise risk management program.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	As of December 31, 2024, the Company has not identified any risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company, including our business strategy, results of operations or financial condition, but there can be no assurance that any such risk will not materially affect the Company in the future.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit and Finance Committee of the Board of Directors has oversight of our cybersecurity program and is responsible for reviewing and assessing the effectiveness of the Company’s cybersecurity and data protection policies, procedures and resource commitment, including key risk areas and mitigation strategies. As part of this process, the Audit and Finance Committee receives regular updates from the Chief Digital and Technology Officer and the Chief Security Officer on critical issues related to our information security risks, cybersecurity strategy, supplier risk and business continuity capabilities. The Audit and Finance Committee has also added a leading cybersecurity incident and response firm to serve as its advisor on cybersecurity matters.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	As part of this process, the Audit and Finance Committee receives regular updates from the Chief Digital and Technology Officer and the Chief Security Officer on critical issues related to our information security risks, cybersecurity strategy, supplier risk and business continuity capabilities. The Audit and Finance Committee has also added a leading cybersecurity incident and response firm to serve as its advisor on cybersecurity matters.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our cybersecurity program is managed by our Chief Digital and Technology Officer and our Chief Security Officer. The Audit and Finance Committee of the Board of Directors has oversight of our cybersecurity program and is responsible for reviewing and assessing the effectiveness of the Company’s cybersecurity and data protection policies, procedures and resource commitment, including key risk areas and mitigation strategies.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	We believe our Chief Digital and Technology Officer and our Chief Security Officer have the appropriate knowledge and expertise to effectively manage our cybersecurity program. The Chief Digital and Technology Officer has experience leading enterprise digital transformation efforts for a large multinational corporation and held several leadership and growth positions at a global technology consulting and services firm before joining UnitedHealth Group. Our Chief Security Officer has more than 30 years of experience as a security professional in both the private and public sectors, including in law enforcement. Prior to joining UnitedHealth Group, he served in security leadership roles at several large multinational corporations and has additionally served on cybersecurity advisory boards for some of the largest corporations in the country.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	As part of this process, the Audit and Finance Committee receives regular updates from the Chief Digital and Technology Officer and the Chief Security Officer on critical issues related to our information security risks, cybersecurity strategy, supplier risk and business continuity capabilities.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Basis of Presentation, Uses o_2

Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The Company has prepared the Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates These Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenue [Policy Text Block]	Revenues Premiums Premium revenues are primarily derived from risk-based arrangements in which the premium is typically at a fixed rate per individual served for a one-year period, and the Company assumes the economic risk of funding its customers’ health care and related administrative costs. Premium revenues are recognized in the period in which eligible individuals are entitled to receive health care benefits. Health care premium payments received from the Company’s customers in advance of the service period are recorded as unearned revenues. Fully insured commercial products of U.S. health plans, Medicare Advantage and Medicare Prescription Drug Benefit (Medicare Part D) plans with medical loss ratios (MLRs) as calculated under the definitions in the Patient Protection and Affordable Care Act (ACA) and related federal and state regulations and implementing regulation, falling below certain targets are required to rebate ratable portions of their premiums annually. Commercial premiums within the Company’s individual and small group markets are also subject to the ACA risk adjustment program. Medicare Advantage premium revenue includes the impact of the Centers for Medicare & Medicaid Services (CMS) quality bonuses based on plans’ Star rating. Certain of the Company’s Medicaid business is also subject to state minimum MLR rebates. Premium revenues are recognized based on the estimated premiums earned, net of projected rebates, because the Company is able to reasonably estimate the ultimate premiums of these contracts. The Company also records premium revenues for certain value-based arrangements at its Optum Health care delivery businesses. Under these value-based arrangements, the Company enters into agreements with health plans to stand ready to deliver, integrate, direct and control certain health care services for patients. In exchange, the Company receives a premium that is typically paid on a per-patient per-month basis. The Company considers these value-based arrangements to represent a single performance obligation where premium revenues are recognized in the period in which health care services are made available. The Company’s Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under CMS’ risk adjustment payment methodology. CMS deploys a risk adjustment model which apportions premiums paid to all health plans according to health severity and certain demographic factors. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis and encounter data from hospital inpatient, hospital outpatient and physician treatment settings. The Company and health care providers collect, capture and submit the necessary and available data to CMS within prescribed deadlines. The Company estimates risk adjustment premium revenues based upon the data submitted and expected to be submitted to CMS. Risk adjustment data for the Company’s plans are subject to review by the government, including audit by regulators. See Note 12 for additional information regarding these audits. Products and Services For the Company’s Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors’ members and accordingly, product revenues are reported on a gross basis. Services revenue includes a number of services and products sold through Optum. Optum Health’s service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured for each period based on the progress to date as services are performed or made available to customers. Services revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees’ dependents. Under service fee contracts, the Company receives a monthly fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees’ dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period. As of December 31, 2024 and 2023, accounts receivables related to products and services were $9.9 billion and $8.6 billion, respectively. In 2024 and 2023, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2024 or 2023. For the years ended December 31, 2024, 2023 and 2022, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material. As of December 31, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $12.7 billion, of which approximately half is expected to be recognized in the next three years. See Note 14 for disaggregation of revenue by segment and type.
Medical Costs and Medical Costs Payable [Policy Text Block]	Medical Costs and Medical Costs Payable The Company’s estimate of medical costs payable represents management’s best estimate of its liability for unpaid medical costs as of December 31, 2024. Each period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months. Medical costs and medical costs payable include estimates of the Company’s obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, care activity and other medical cost trends, membership volume and demographics, the introduction of new technologies, benefit plan changes and business mix changes related to products, customers and geography. In developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months.
Cost of Goods and Service [Policy Text Block]	Cost of Products Sold The Company’s cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery, specialty and community pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to unaffiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those unaffiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance and professional services.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents and Investments
Investment, Policy [Policy Text Block]	Investments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments are measured at fair value, with certain exceptions where the Company has elected to measure investments with unobservable inputs at cost, subject to fair value adjustments upon an impairment or a transaction of the same or similar security. Changes in fair value of equity investments are recognized in net earnings. The Company excludes unrealized gains and losses on available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold. The Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances which may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings.
Assets Under Management [Policy Text Block]	Assets Under Management In July 2024, the Company amended its Medicare Supplement Program with a membership organization (the Medicare Supplement Program). The amendments provide the Company the right to use a trade name and other intellectual property in marketing efforts for Medicare Supplement offerings. Amounts previously reported as assets under management are now included within the Company’s Consolidated Balance Sheet based upon their classification. For periods prior to the amended Medicare Supplement Program, the Company excluded the effects of certain balance sheet amounts in its Consolidated Statements of Cash Flows, while these effects are included for periods after the amendments.
Receivable [Policy Text Block]	Other Current Receivables Other current receivables include amounts due from pharmaceutical manufacturers for rebates and Medicare Part D drug discounts, loans to care providers in response to the Change Healthcare cyberattack, accrued interest and other miscellaneous amounts due to the Company. The Company’s pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers’ products by its affiliated and unaffiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2024 and 2023, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $12.5 billion and $11.0 billion, respectively.
Prepaid and Other Current Assets Policy	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets included pharmaceutical drug and supplies inventory of $3.8 billion and $2.8 billion as of December 31, 2024 and 2023, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Equipment and Capitalized Software Property, equipment and capitalized software are stated at cost, net of accumulated depreciation and amortization. Capitalized software consists of certain costs incurred in the development of internal-use software, including external direct costs of materials and services and applicable payroll costs of employees devoted to specific software development. The Company calculates depreciation and amortization using the straight-line method over the estimated useful lives of the assets. The useful lives for property, equipment and capitalized software are: Furniture, fixtures and equipment 3 to 10 years Buildings 35 to 40 years Capitalized software 3 to 5 years Leasehold improvements are depreciated over the shorter of the remaining lease term or their estimated useful economic life.
Lessee, Leases [Policy Text Block]	Operating Leases The Company leases facilities and equipment under long-term operating leases which are non-cancelable and expire on various dates. At the lease commencement date, lease right-of-use (ROU) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period closely matching the lease term. lease liabilities are included in other current liabilities and other liabilities in the Company’s Consolidated Balance Sheet
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs impairment tests. The Company may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital levels and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill. There was no impairment of goodwill during the years ended December 31, 2024, 2023 and 2022.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets The Company’s finite-lived intangible assets are subject to impairment tests when events or circumstances indicate an intangible asset (or asset group) may be impaired. The Company’s indefinite-lived intangible assets are also tested for impairment annually. There was no impairment of intangible assets during the years ended December 31, 2024, 2023 and 2022.
Other Current Liabilities [Policy Text Block]	Other Current Liabilities Other current liabilities include health savings account deposits ($13.7 billion and $13.5 billion as of December 31, 2024 and 2023, respectively), accruals for premium rebates payable, the current portion of future policy benefits and customer balances.
Deferred Policy Acquisition Costs, Policy [Policy Text Block]	Policy Acquisition Costs The Company’s short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days’ notice. Costs related to the acquisition and renewal of short duration customer contracts are primarily charged to expense as incurred.
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside of the Company’s control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2024 and 2023: (in millions) 2024 2023 Redeemable noncontrolling interests, beginning of period $ 4,498 $ 4,897 Net earnings 174 188 Acquisitions 33 122 Redemptions (280) (730) Distributions (125) (144) Fair value and other adjustments 23 165 Redeemable noncontrolling interests, end of period $ 4,323 $ 4,498
Share-based Payment Arrangement [Policy Text Block]	Share-Based Compensation four four
Earnings Per Share, Policy [Policy Text Block]	Net Earnings Per Common Share

Fair Value Fair Value (Policies

Fair Value Fair Value (Policies)	12 Months Ended
	Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Measurement, Policy [Policy Text Block]	Certain assets and liabilities are measured at fair value in the Consolidated Financial Statements or have fair values disclosed in the Notes to the Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety based on the lowest level input which is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The fair value hierarchy is summarized as follows: Level 1 — Quoted prices (unadjusted) for identical assets/liabilities in active markets. Level 2 — Other observable inputs, either directly or indirectly, including: • Quoted prices for similar assets/liabilities in active markets; • Quoted prices for identical or similar assets/liabilities in inactive markets (e.g., few transactions, limited information, noncurrent prices, high variability over time); • Inputs other than quoted prices observable for the asset/liability (e.g., interest rates, yield curves, implied volatilities, credit spreads); and • Inputs corroborated by other observable market data. Level 3 — Unobservable inputs cannot be corroborated by observable market data. There were no transfers in or out of Level 3 financial assets or liabilities during the years ended December 31, 2024 or 2023. Nonfinancial assets and liabilities or financial assets and liabilities measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. For the years ended December 31, 2024, 2023 and 2022, the Company recognized $710 million, $276 million and $211 million respectively, of unrealized gains in investment and other income related to fair value adjustments on equity securities primarily in the Company’s venture portfolio, based upon transactions of the same or similar security. The assets and liabilities within our South American operations held for sale as of December 31, 2024 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no other significant fair value adjustments for these assets and liabilities recorded during the years ended December 31, 2024, 2023 or 2022. The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the tables below: Cash and Cash Equivalents. The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. Fair values of cash equivalent instruments which do not trade on a regular basis in active markets are classified as Level 2. Debt and Equity Securities. Fair values of debt securities and equity securities reported at fair value on a recurring basis are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (pricing service), which generally uses quoted or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, and, if necessary, makes adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs currently observable in the markets for similar securities. Inputs often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and nonbinding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to prices reported by a secondary pricing source, such as its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company’s internal price verification procedures and reviews of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment to the prices obtained from the pricing service. Fair values of debt securities which do not trade on a regular basis in active markets but are priced using other observable inputs are classified as Level 2. Fair value estimates for Level 1 and Level 2 equity securities reported at fair value on a recurring basis are based on quoted market prices for actively traded equity securities and/or other market data for the same or comparable instruments and transactions in establishing the prices. The fair values of Level 3 investments in corporate bonds, which are not a significant portion of our investments, are estimated using valuation techniques relying heavily on management assumptions and qualitative observations. Throughout the procedures discussed above in relation to the Company’s processes for validating third-party pricing information, the Company validates the understanding of assumptions and inputs used in security pricing and determines the proper classification in the hierarchy based on such understanding. Long-Term Debt. The fair values of the Company’s long-term debt are estimated and classified using the same methodologies as the Company’s investments in debt securities.

Schedule I (Policies)

Schedule I (Policies)	12 Months Ended
	Dec. 31, 2024
Condensed Financial Statements, Captions [Line Items]
Basis of Presentation and Significant Accounting Policies [Text Block]	Basis of Presentation, Use of Estimates and Significant Accounting Policies Basis of Presentation The Company has prepared the Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. Use of Estimates These Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. Revenues Premiums Premium revenues are primarily derived from risk-based arrangements in which the premium is typically at a fixed rate per individual served for a one-year period, and the Company assumes the economic risk of funding its customers’ health care and related administrative costs. Premium revenues are recognized in the period in which eligible individuals are entitled to receive health care benefits. Health care premium payments received from the Company’s customers in advance of the service period are recorded as unearned revenues. Fully insured commercial products of U.S. health plans, Medicare Advantage and Medicare Prescription Drug Benefit (Medicare Part D) plans with medical loss ratios (MLRs) as calculated under the definitions in the Patient Protection and Affordable Care Act (ACA) and related federal and state regulations and implementing regulation, falling below certain targets are required to rebate ratable portions of their premiums annually. Commercial premiums within the Company’s individual and small group markets are also subject to the ACA risk adjustment program. Medicare Advantage premium revenue includes the impact of the Centers for Medicare & Medicaid Services (CMS) quality bonuses based on plans’ Star rating. Certain of the Company’s Medicaid business is also subject to state minimum MLR rebates. Premium revenues are recognized based on the estimated premiums earned, net of projected rebates, because the Company is able to reasonably estimate the ultimate premiums of these contracts. The Company also records premium revenues for certain value-based arrangements at its Optum Health care delivery businesses. Under these value-based arrangements, the Company enters into agreements with health plans to stand ready to deliver, integrate, direct and control certain health care services for patients. In exchange, the Company receives a premium that is typically paid on a per-patient per-month basis. The Company considers these value-based arrangements to represent a single performance obligation where premium revenues are recognized in the period in which health care services are made available. The Company’s Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under CMS’ risk adjustment payment methodology. CMS deploys a risk adjustment model which apportions premiums paid to all health plans according to health severity and certain demographic factors. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis and encounter data from hospital inpatient, hospital outpatient and physician treatment settings. The Company and health care providers collect, capture and submit the necessary and available data to CMS within prescribed deadlines. The Company estimates risk adjustment premium revenues based upon the data submitted and expected to be submitted to CMS. Risk adjustment data for the Company’s plans are subject to review by the government, including audit by regulators. See Note 12 for additional information regarding these audits. Products and Services For the Company’s Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors’ members and accordingly, product revenues are reported on a gross basis. Services revenue includes a number of services and products sold through Optum. Optum Health’s service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured for each period based on the progress to date as services are performed or made available to customers. Services revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees’ dependents. Under service fee contracts, the Company receives a monthly fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees’ dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period. As of December 31, 2024 and 2023, accounts receivables related to products and services were $9.9 billion and $8.6 billion, respectively. In 2024 and 2023, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2024 or 2023. For the years ended December 31, 2024, 2023 and 2022, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material. As of December 31, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $12.7 billion, of which approximately half is expected to be recognized in the next three years. See Note 14 for disaggregation of revenue by segment and type. Medical Costs and Medical Costs Payable The Company’s estimate of medical costs payable represents management’s best estimate of its liability for unpaid medical costs as of December 31, 2024. Each period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months. Medical costs and medical costs payable include estimates of the Company’s obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, care activity and other medical cost trends, membership volume and demographics, the introduction of new technologies, benefit plan changes and business mix changes related to products, customers and geography. In developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months. Cost of Products Sold The Company’s cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery, specialty and community pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to unaffiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those unaffiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance and professional services. Cash, Cash Equivalents and Investments Cash and cash equivalents are highly liquid investments having an original maturity of three months or less. The fair value of cash and cash equivalents approximates their carrying value because of the short maturity of the instruments. Investments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments are measured at fair value, with certain exceptions where the Company has elected to measure investments with unobservable inputs at cost, subject to fair value adjustments upon an impairment or a transaction of the same or similar security. Changes in fair value of equity investments are recognized in net earnings. The Company excludes unrealized gains and losses on available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold. The Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances which may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings. New information and the passage of time can change these judgments. The Company manages its investment portfolio to limit its exposure to any one issuer or market sector, and largely limits its investments to investment grade quality. Assets Under Management In July 2024, the Company amended its Medicare Supplement Program with a membership organization (the Medicare Supplement Program). The amendments provide the Company the right to use a trade name and other intellectual property in marketing efforts for Medicare Supplement offerings. Amounts previously reported as assets under management are now included within the Company’s Consolidated Balance Sheet based upon their classification. For periods prior to the amended Medicare Supplement Program, the Company excluded the effects of certain balance sheet amounts in its Consolidated Statements of Cash Flows, while these effects are included for periods after the amendments. Other Current Receivables Other current receivables include amounts due from pharmaceutical manufacturers for rebates and Medicare Part D drug discounts, loans to care providers in response to the Change Healthcare cyberattack, accrued interest and other miscellaneous amounts due to the Company. The Company’s pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers’ products by its affiliated and unaffiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2024 and 2023, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $12.5 billion and $11.0 billion, respectively. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets included pharmaceutical drug and supplies inventory of $3.8 billion and $2.8 billion as of December 31, 2024 and 2023, respectively. Property, Equipment and Capitalized Software Property, equipment and capitalized software are stated at cost, net of accumulated depreciation and amortization. Capitalized software consists of certain costs incurred in the development of internal-use software, including external direct costs of materials and services and applicable payroll costs of employees devoted to specific software development. The Company calculates depreciation and amortization using the straight-line method over the estimated useful lives of the assets. The useful lives for property, equipment and capitalized software are: Furniture, fixtures and equipment 3 to 10 years Buildings 35 to 40 years Capitalized software 3 to 5 years Leasehold improvements are depreciated over the shorter of the remaining lease term or their estimated useful economic life. Operating Leases The Company leases facilities and equipment under long-term operating leases which are non-cancelable and expire on various dates. At the lease commencement date, lease right-of-use (ROU) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period closely matching the lease term. The Company’s ROU assets are included in other assets, and lease liabilities are included in other current liabilities and other liabilities in the Company’s Consolidated Balance Sheet Goodwill To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs impairment tests. The Company may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital levels and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill. There was no impairment of goodwill during the years ended December 31, 2024, 2023 and 2022. Intangible Assets The Company’s finite-lived intangible assets are subject to impairment tests when events or circumstances indicate an intangible asset (or asset group) may be impaired. The Company’s indefinite-lived intangible assets are also tested for impairment annually. There was no impairment of intangible assets during the years ended December 31, 2024, 2023 and 2022. Other Current Liabilities Other current liabilities include health savings account deposits ($13.7 billion and $13.5 billion as of December 31, 2024 and 2023, respectively), accruals for premium rebates payable, the current portion of future policy benefits and customer balances. Policy Acquisition Costs The Company’s short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days’ notice. Costs related to the acquisition and renewal of short duration customer contracts are primarily charged to expense as incurred. Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside of the Company’s control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2024 and 2023: (in millions) 2024 2023 Redeemable noncontrolling interests, beginning of period $ 4,498 $ 4,897 Net earnings 174 188 Acquisitions 33 122 Redemptions (280) (730) Distributions (125) (144) Fair value and other adjustments 23 165 Redeemable noncontrolling interests, end of period $ 4,323 $ 4,498 Share-Based Compensation The Company recognizes compensation expense for share-based awards, including stock options and restricted stock and restricted stock units (collectively, restricted shares), on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. Restricted shares vest ratably, primarily over four four Net Earnings Per Common Share
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside of the Company’s control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2024 and 2023: (in millions) 2024 2023 Redeemable noncontrolling interests, beginning of period $ 4,498 $ 4,897 Net earnings 174 188 Acquisitions 33 122 Redemptions (280) (730) Distributions (125) (144) Fair value and other adjustments 23 165 Redeemable noncontrolling interests, end of period $ 4,323 $ 4,498
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Basis of Presentation and Significant Accounting Policies [Text Block]	Basis of Presentation UnitedHealth Group’s parent company financial information has been derived from its consolidated financial statements and should be read in conjunction with the consolidated financial statements included in this Form 10-K. The accounting policies for the registrant are the same as those described in Note 2 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Subsidiary Transactions Investment in Subsidiaries. UnitedHealth Group’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries.

Basis of Presentation, Uses o_3

Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Table Text Block]	A summary of property, equipment and capitalized software is as follows: (in millions) December 31, 2024 December 31, 2023 Land and improvements $ 364 $ 712 Buildings and improvements 4,215 5,573 Computer equipment 2,267 2,007 Furniture and fixtures 1,694 2,375 Less accumulated depreciation (3,645) (4,210) Property and equipment, net 4,895 6,457 Capitalized software 8,984 7,822 Less accumulated amortization (3,326) (2,829) Capitalized software, net 5,658 4,993 Total property, equipment and capitalized software, net $ 10,553 $ 11,450
Redeemable Noncontrolling Interest [Table Text Block]	The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2024 and 2023: (in millions) 2024 2023 Redeemable noncontrolling interests, beginning of period $ 4,498 $ 4,897 Net earnings 174 188 Acquisitions 33 122 Redemptions (280) (730) Distributions (125) (144) Fair value and other adjustments 23 165 Redeemable noncontrolling interests, end of period $ 4,323 $ 4,498
Useful Life [Member]
Property, Plant and Equipment [Table Text Block]	The useful lives for property, equipment and capitalized software are: Furniture, fixtures and equipment 3 to 10 years Buildings 35 to 40 years Capitalized software 3 to 5 years

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2024
Short-Term and Long-Term Investments [Table Text Block]	A summary of debt securities by major security type is as follows: (in millions) Amortized Gross Gross Fair December 31, 2024 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,600 $ 1 $ (274) $ 4,327 State and municipal obligations 7,357 2 (375) 6,984 Corporate obligations 24,391 56 (1,140) 23,307 U.S. agency mortgage-backed securities 10,577 1 (994) 9,584 Non-U.S. agency mortgage-backed securities 2,890 2 (175) 2,717 Total debt securities - available-for-sale 49,815 62 (2,958) 46,919 Debt securities - held-to-maturity: U.S. government and agency obligations 444 — (2) 442 State and municipal obligations 28 — (2) 26 Corporate obligations 40 — — 40 Total debt securities - held-to-maturity 512 — (4) 508 Total debt securities $ 50,327 $ 62 $ (2,962) $ 47,427 December 31, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,674 $ 3 $ (234) $ 4,443 State and municipal obligations 7,636 39 (322) 7,353 Corporate obligations 23,136 67 (1,186) 22,017 U.S. agency mortgage-backed securities 8,982 22 (708) 8,296 Non-U.S. agency mortgage-backed securities 3,023 3 (240) 2,786 Total debt securities - available-for-sale 47,451 134 (2,690) 44,895 Debt securities - held-to-maturity: U.S. government and agency obligations 506 1 (6) 501 State and municipal obligations 28 — (2) 26 Corporate obligations 69 — — 69 Total debt securities - held-to-maturity 603 1 (8) 596 Total debt securities $ 48,054 $ 135 $ (2,698) $ 45,491
Investments by Contractual Maturity [Table Text Block]	The amortized cost and fair value of debt securities as of December 31, 2024, by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Fair Amortized Fair Due in one year or less $ 3,952 $ 3,932 $ 320 $ 319 Due after one year through five years 14,845 14,384 161 161 Due after five years through ten years 12,110 11,213 14 13 Due after ten years 5,441 5,089 17 15 U.S. agency mortgage-backed securities 10,577 9,584 — — Non-U.S. agency mortgage-backed securities 2,890 2,717 — — Total debt securities $ 49,815 $ 46,919 $ 512 $ 508
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value	The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Gross Fair Gross Fair Gross December 31, 2024 U.S. government and agency obligations $ 1,475 $ (51) $ 2,152 $ (223) $ 3,627 $ (274) State and municipal obligations 2,593 (58) 4,085 (317) 6,678 (375) Corporate obligations 7,402 (213) 11,449 (927) 18,851 (1,140) U.S. agency mortgage-backed securities 4,791 (191) 4,674 (803) 9,465 (994) Non-U.S. agency mortgage-backed securities 416 (5) 1,863 (170) 2,279 (175) Total debt securities - available-for-sale $ 16,677 $ (518) $ 24,223 $ (2,440) $ 40,900 $ (2,958) December 31, 2023 U.S. government and agency obligations $ 1,270 $ (7) $ 2,077 $ (227) $ 3,347 $ (234) State and municipal obligations 907 (7) 4,063 (315) 4,970 (322) Corporate obligations 1,826 (17) 14,696 (1,169) 16,522 (1,186) U.S. agency mortgage-backed securities 1,337 (12) 5,069 (696) 6,406 (708) Non-U.S. agency mortgage-backed securities 279 (6) 2,202 (234) 2,481 (240) Total debt securities - available-for-sale $ 5,619 $ (49) $ 28,107 $ (2,641) $ 33,726 $ (2,690)

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block]	The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total December 31, 2024 Cash and cash equivalents $ 25,248 $ 64 $ — $ 25,312 Debt securities - available-for-sale: U.S. government and agency obligations 4,194 133 — 4,327 State and municipal obligations — 6,984 — 6,984 Corporate obligations 29 22,841 437 23,307 U.S. agency mortgage-backed securities — 9,584 — 9,584 Non-U.S. agency mortgage-backed securities — 2,717 — 2,717 Total debt securities - available-for-sale 4,223 42,259 437 46,919 Equity securities 1,859 24 65 1,948 Total assets at fair value $ 31,330 $ 42,347 $ 502 $ 74,179 Percentage of total assets at fair value 42 % 57 % 1 % 100 % December 31, 2023 Cash and cash equivalents $ 25,345 $ 82 $ — $ 25,427 Debt securities - available-for-sale: U.S. government and agency obligations 4,167 276 — 4,443 State and municipal obligations — 7,353 — 7,353 Corporate obligations 15 21,800 202 22,017 U.S. agency mortgage-backed securities — 8,296 — 8,296 Non-U.S. agency mortgage-backed securities — 2,786 — 2,786 Total debt securities - available-for-sale 4,182 40,511 202 44,895 Equity securities 2,468 16 69 2,553 Assets under management 1,505 2,140 110 3,755 Total assets at fair value $ 33,500 $ 42,749 $ 381 $ 76,630 Percentage of total assets at fair value 44 % 55 % 1 % 100 %
Fair Value Measurements, Nonrecurring [Table Text Block]	The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total Total Carrying Value December 31, 2024 Debt securities - held-to-maturity $ 482 $ 26 $ — $ 508 $ 512 Long-term debt and other financing obligations $ — $ 70,565 $ — $ 70,565 $ 75,604 December 31, 2023 Debt securities - held-to-maturity $ 524 $ 72 $ — $ 596 $ 603 Long-term debt and other financing obligations $ — $ 59,851 $ — $ 59,851 $ 61,449

Property, Plant, and Capitali_2

Property, Plant, and Capitalized Software (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment [Table Text Block]	A summary of property, equipment and capitalized software is as follows: (in millions) December 31, 2024 December 31, 2023 Land and improvements $ 364 $ 712 Buildings and improvements 4,215 5,573 Computer equipment 2,267 2,007 Furniture and fixtures 1,694 2,375 Less accumulated depreciation (3,645) (4,210) Property and equipment, net 4,895 6,457 Capitalized software 8,984 7,822 Less accumulated amortization (3,326) (2,829) Capitalized software, net 5,658 4,993 Total property, equipment and capitalized software, net $ 10,553 $ 11,450

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill [Line Items]
Schedule of Goodwill [Table Text Block]	Changes in the carrying amount of goodwill, by reportable segment, were as follows: (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Consolidated Balance at January 1, 2023 $ 27,395 $ 29,238 $ 17,244 $ 19,475 $ 93,352 Acquisitions 296 8,023 1,802 — 10,121 Foreign currency effects and other adjustments, net 187 (182) 261 (7) 259 Balance at December 31, 2023 27,878 37,079 19,307 19,468 103,732 Acquisitions — 2,071 — 2,305 4,376 Dispositions, foreign currency effects and other adjustments, net (717) (324) (327) (6) (1,374) Balance at December 31, 2024 $ 27,161 $ 38,826 $ 18,980 $ 21,767 $ 106,734
Schedule of Acquired Intangible Assets by Major Class [Table Text Block]	The gross carrying value, accumulated amortization and net carrying value of other intangible assets were as follows: December 31, 2024 December 31, 2023 (in millions) Gross Carrying Value Accumulated Amortization Net Carrying Value Gross Carrying Value Accumulated Amortization Net Carrying Value Customer-related $ 17,190 $ (6,675) $ 10,515 $ 16,636 $ (5,909) $ 10,727 Trademarks and technology 2,917 (1,284) 1,633 2,508 (958) 1,550 Trade names, trademarks, operating licenses and certificates and other indefinite-lived 10,454 — 10,454 2,116 — 2,116 Other 1,057 (391) 666 1,213 (412) 801 Total $ 31,618 $ (8,350) $ 23,268 $ 22,473 $ (7,279) $ 15,194
Schedule of Intangible Assets Acquired as Part of Business Combination [Table Text Block]	The fair values and weighted-average useful lives assigned to intangible assets as a result of transactions completed during years ended: 2024 2023 (in millions, except years) Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Customer-related $ 1,258 12 years $ 477 12 years Trademarks and technology 527 6 years 226 5 years Other 22 8 years 44 9 years Total finite-lived $ 1,807 10 years $ 747 9 years Total indefinite-lived - trade names, trademarks, operating licenses and certificates and other 8,795 1,427 Total intangible assets $ 10,602 $ 2,174
Schedule of Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated full year amortization expense relating to intangible assets for each of the next five years ending December 31 is as follows: (in millions) 2025 $ 1,655 2026 1,503 2027 1,424 2028 1,344 2029 1,211

Medical Costs Payable (Tables)

Medical Costs Payable (Tables)	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]	The following table shows the components of the change in medical costs payable for the years ended December 31: (in millions) 2024 2023 2022 Medical costs payable, beginning of period $ 32,395 $ 29,056 $ 24,483 Acquisitions (dispositions), net (755) 1 308 Reported medical costs: Current year 264,885 242,734 211,252 Prior years (700) (840) (410) Total reported medical costs 264,185 241,894 210,842 Medical payments: Payments for current year (231,890) (211,380) (184,049) Payments for prior years (29,532) (27,176) (22,528) Total medical payments (261,422) (238,556) (206,577) Less: medical costs payable included within businesses held for sale (179) — — Medical costs payable, end of period $ 34,224 $ 32,395 $ 29,056
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]	The following is information about incurred and paid medical cost development as of December 31, 2024: Net Incurred Medical Costs (in millions) For the Years Ended December 31, Year 2023 2024 2023 $ 242,734 $ 242,156 2024 264,885 Total $ 507,041 Net Cumulative Medical Payments (in millions) For the Years Ended December 31, Year 2023 2024 2023 $ (211,380) $ (240,112) 2024 (231,890) Total (472,002) Net remaining outstanding liabilities prior to 2023 119 Acquisitions (dispositions), net (755) Medical costs payable included within businesses held for sale (179) Total medical costs payable $ 34,224

Short-Term Borrowings and Lon_2

Short-Term Borrowings and Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Instrument [Line Items]
Short-Term Borrowings and Long-Term Debt [Table Text Block]	Short-term borrowings and senior unsecured long-term debt consisted of commercial paper and notes as follows: Carrying Value as of December 31, Carrying Value as of December 31, (in millions, except percentages) 2024 2023 (continued) 2024 2023 Commercial paper $ 1,300 $ 1,088 $1,000 4.625%, Jul 2035 971 1,014 $750 3.5%, Feb 2024 — 750 $850 5.8%, Mar 2036 838 838 $1,000 0.55%, May 2024 — 999 $500 6.5%, Jun 2037 492 491 $750 2.375%, Aug 2024 — 750 $650 6.625%, Nov 2037 641 640 $500 5%, Oct 2024 — 499 $1,100 6.875%, Feb 2038 1,079 1,078 $2,000 3.75%, Jul 2025 1,999 1,997 $1,250 3.5%, Aug 2039 1,243 1,242 $750 5.15%, Oct 2025 749 748 $1,000 2.75%, May 2040 970 968 $300 3.7%, Dec 2025 300 299 $300 5.7%, Oct 2040 296 296 $500 1.25%, Jan 2026 499 498 $350 5.95%, Feb 2041 346 346 $1,000 3.1%, Mar 2026 999 998 $1,500 3.05%, May 2041 1,485 1,484 $1,000 1.15%, May 2026 953 924 $600 4.625%, Nov 2041 590 590 $500 floating rate, Jul 2026 499 — $502 4.375%, Mar 2042 487 486 $650 4.75%, Jul 2026 648 — $625 3.95%, Oct 2042 610 609 $750 3.45%, Jan 2027 749 748 $750 4.25%, Mar 2043 737 736 $500 4.6%, Apr 2027 496 — $1,500 5.5%, Jul 2044 1,475 — $625 3.375%, Apr 2027 623 622 $2,000 4.75%, Jul 2045 1,976 1,975 $600 3.7%, May 2027 598 598 $750 4.2%, Jan 2047 739 739 $950 2.95%, Oct 2027 946 944 $725 4.25%, Apr 2047 718 718 $1,000 5.25%, Feb 2028 998 1,011 $950 3.75%, Oct 2047 935 935 $1,150 3.85%, Jun 2028 1,147 1,146 $1,350 4.25%, Jun 2048 1,332 1,331 $850 3.875%, Dec 2028 847 846 $1,100 4.45%, Dec 2048 1,087 1,087 $1,250 4.25%, Jan 2029 1,221 1,238 $1,250 3.7%, Aug 2049 1,237 1,236 $400 4.7%, Apr 2029 398 — $1,250 2.9%, May 2050 1,212 1,211 $900 4%, May 2029 854 862 $2,000 3.25%, May 2051 1,972 1,972 $1,000 2.875%, Aug 2029 902 908 $2,000 4.75%, May 2052 1,966 1,966 $1,250 4.8%, Jan 2030 1,225 — $2,000 5.875%, Feb 2053 1,968 1,968 $1,250 5.3%, Feb 2030 1,243 1,275 $2,000 5.05%, Apr 2053 1,969 1,969 $1,250 2%, May 2030 1,240 1,238 $1,750 5.375%, Apr 2054 1,729 — $1,000 4.9%, Apr 2031 982 — $2,750 5.625%, Jul 2054 2,724 — $1,500 2.3%, May 2031 1,271 1,290 $1,250 3.875%, Aug 2059 1,229 1,229 $1,500 4.95%, Jan 2032 1,489 — $1,000 3.125%, May 2060 967 966 $1,500 4.2%, May 2032 1,372 1,412 $1,000 4.95%, May 2062 981 981 $2,000 5.35%, Feb 2033 1,966 2,046 $1,500 6.05%, Feb 2063 1,466 1,466 $1,500 4.5%, Apr 2033 1,410 1,463 $1,750 5.2%, Apr 2063 1,710 1,709 $1,250 5%, Apr 2034 1,214 — $1,100 5.5%, Apr 2064 1,085 — $2,000 5.15%, Jul 2034 1,959 — $1,850 5.75%, Jul 2064 1,822 — Total short-term borrowings and long-term debt $ 76,180 $ 61,473
Schedule of Maturities of Long-term Debt [Table Text Block]	Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2025 $ 4,548 2026 3,756 2027 3,531 2028 3,106 2029 3,656 Thereafter 59,908

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Contingency [Line Items]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The components of income before income taxes, based upon tax jurisdiction, for the years ended December 31 are as follows: (in millions) 2024 2023 2022 Income before income taxes: Domestic $ 28,264 $ 29,210 $ 26,685 Foreign (8,193) (98) (342) Total income before income taxes $ 20,071 $ 29,112 $ 26,343
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for income taxes for the years ended December 31 are as follows: (in millions) 2024 2023 2022 Current Provision: Federal $ 3,453 $ 4,418 $ 4,842 State and local 416 716 855 Foreign 1,256 1,079 680 Total current provision 5,125 6,213 6,377 Deferred benefit (296) (245) (673) Total provision for income taxes $ 4,829 $ 5,968 $ 5,704
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The reconciliation of the tax provision at the U.S. federal statutory rate to the provision for income taxes and the effective tax rate for the years ended December 31 is as follows: (in millions, except percentages) 2024 2023 2022 Tax provision at the U.S. federal statutory rate $ 4,215 21.0 % $ 6,114 21.0 % $ 5,532 21.0 % State income taxes, net of federal benefit 343 1.7 567 2.0 621 2.4 Share-based awards - excess tax benefit (96) (0.5) (75) (0.3) (110) (0.4) Non-deductible compensation 171 0.9 174 0.6 150 0.6 Foreign rate differential (369) (1.8) (442) (1.5) (265) (1.0) Tax effect of dispositions and other strategic transactions 1,215 6.1 (29) (0.1) (215) (0.8) Other, net (650) (3.3) (341) (1.2) (9) (0.1) Provision for income taxes $ 4,829 24.1 % $ 5,968 20.5 % $ 5,704 21.7 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The components of deferred income tax assets and liabilities as of December 31 are as follows: (in millions) 2024 2023 Deferred income tax assets: Accrued expenses and allowances $ 1,055 $ 754 U.S. federal and state net operating loss carryforwards 442 417 Share-based compensation 189 173 Nondeductible liabilities 343 329 Non-U.S. tax loss carryforwards 21 1,061 Lease liability 846 930 Net unrealized losses on investments 669 586 Other-domestic 597 327 Other-non-U.S. 59 484 Subtotal 4,221 5,061 Less: valuation allowances (397) (366) Total deferred income tax assets 3,824 4,695 Deferred income tax liabilities: U.S. federal and state intangible assets (4,479) (3,712) Non-U.S. goodwill and intangible assets (82) (731) Capitalized software (288) (415) Depreciation and amortization (400) (371) Prepaid expenses (374) (326) Outside basis in partnerships (960) (811) Lease right-of-use asset (833) (914) Other-non-U.S. (28) (436) Total deferred income tax liabilities (7,444) (7,716) Net deferred income tax liabilities $ (3,620) $ (3,021)
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	A reconciliation of the beginning and ending amount of unrecognized tax benefits as of December 31 is as follows: (in millions) 2024 2023 2022 Gross unrecognized tax benefits, beginning of period $ 3,716 $ 3,081 $ 2,310 Gross increases: Current year tax positions 578 782 586 Prior year tax positions 10 97 206 Gross decreases: Prior year tax positions (121) (212) (21) Statute of limitations lapses and settlements (60) (32) — Gross unrecognized tax benefits, end of period $ 4,123 $ 3,716 $ 3,081

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2024
Shareholders' Equity [Abstract]
Share Repurchase Activity	A summary of common share repurchases for the years ended December 31, 2024 and 2023 is as follows: Years Ended December 31, (in millions, except per share data) 2024 2023 Common share repurchases, shares 17 16 Common share repurchases, average price per share $ 529.85 $ 493.79 Common share repurchases, aggregate cost $ 8,942 $ 8,000 Board authorized shares remaining 33 15
Dividends Declared	The following table provides details of the Company’s 2024 dividend payments: Payment Date Amount per Share Total Amount Paid (in millions) March 19 $ 1.88 $ 1,729 June 25 2.10 1,935 September 24 2.10 1,937 December 17 2.10 1,932

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock Option Activity [Table Text Block]	Stock option activity for the year ended December 31, 2024 is summarized in the table below: Shares Weighted- Weighted- Aggregate (in millions) (in years) (in millions) Outstanding at beginning of period 21 $ 320 Granted 3 522 Exercised (6) 253 Forfeited (1) 480 Outstanding at end of period 17 370 5.6 $ 2,338 Exercisable at end of period 10 298 4.2 2,115 Vested and expected to vest, end of period 17 368 5.5 2,335
Restricted Share Activity [Table Text Block]	Restricted share activity for the year ended December 31, 2024 is summarized in the table below: (shares in millions) Shares Weighted-Average Nonvested at beginning of period 4 $ 449 Granted 2 523 Vested (2) 435 Nonvested at end of period 4 489
Other Share-Based Compensation Data [Table Text Block]	Other Share-Based Compensation Data (in millions, except per share amounts) For the Years Ended December 31, 2024 2023 2022 Stock Options Weighted-average grant date fair value of shares granted, per share $ 138 $ 134 $ 116 Total intrinsic value of stock options exercised 1,886 1,325 1,419 Restricted Shares Weighted-average grant date fair value of shares granted, per share 523 493 483 Total fair value of restricted shares vested 690 803 760 Employee Stock Purchase Plan Number of shares purchased 1 1 1 Share-Based Compensation Items Share-based compensation expense, before tax $ 1,018 $ 1,059 $ 925 Share-based compensation expense, net of tax effects 896 937 836 Income tax benefit realized from share-based award exercises 216 231 207 (in millions, except years) December 31, 2024 Unrecognized compensation expense related to share awards $ 1,099 Weighted-average years to recognize compensation expense 1.3
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The principal assumptions the Company used in calculating grant-date fair value for stock options were as follows: For the Years Ended December 31, 2024 2023 2022 Risk-free interest rate 3.6% - 4.4% 3.8% - 4.6% 1.9% - 4.3% Expected volatility 25.5% - 30.7% 29.7% - 30.6% 30.6% - 30.8% Expected dividend yield 1.4% - 1.5% 1.3% - 1.5% 1.2% Forfeiture rate 5.0% 5.0% 5.0% Expected life in years 4.6 4.6 4.7

Commitments and Contingencies_2

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	As of December 31, 2024, future minimum annual lease payments under all non-cancelable operating leases were as follows: (in millions) Future Minimum Lease Payments 2025 $ 1,014 2026 876 2027 688 2028 568 2029 583 Thereafter 2,465 Total future minimum lease payments 6,194 Less imputed interest (1,305) Total $ 4,889

Dispositions and Held for Sal_2

Dispositions and Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposed Assets and Liabilities [Table Text Block]	The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of December 31, 2024, respectively, were as follows: (in millions) Brazil Businesses Assets Cash and cash equivalents $ 778 $ 219 Accounts receivable and other current assets 515 573 Long-term investments 788 41 Property, equipment and capitalized software 1,052 641 Deferred tax assets 1,035 — Goodwill and other intangible assets 317 413 Other long-term assets 439 231 Remeasurement of assets of businesses held for sale to fair value less cost to sell (1) — (1,224) Total assets $ 4,924 $ 894 Liabilities Medical costs payable $ 701 $ 179 Accounts payable and other current liabilities 834 338 Other long-term liabilities 136 504 Total liabilities $ 1,671 $ 1,021 (1) Includes the effect of $855 million of cumulative foreign currency translation losses and $56 million of noncontrolling interests.

Segment Financial Information_2

Segment Financial Information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Financial Information [Table Text Block]	The following table presents the reportable segment financial information: Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated 2024 Revenues - unaffiliated customers: Premiums $ 286,004 $ 22,806 $ — $ — $ — $ 22,806 $ — $ 308,810 Products — 277 174 49,775 — 50,226 — 50,226 Services 9,791 16,153 6,466 3,630 — 26,249 — 36,040 Total revenues - unaffiliated customers 295,795 39,236 6,640 53,405 — 99,281 — 395,076 Total revenues - affiliated customers — 63,883 11,881 79,512 (4,389) 150,887 (150,887) — Investment and other income 2,413 2,239 236 314 — 2,789 — 5,202 Total revenues $ 298,208 $ 105,358 $ 18,757 $ 133,231 $ (4,389) $ 252,957 $ (150,887) $ 400,278 Total operating costs (a) $ 282,624 $ 97,588 $ 15,660 $ 127,395 $ (4,389) $ 236,254 $ (150,887) $ 367,991 Earnings from operations $ 15,584 $ 7,770 $ 3,097 $ 5,836 $ — $ 16,703 $ — $ 32,287 Interest expense — — — — — — (3,906) (3,906) Loss on sale of subsidiary and subsidiaries held for sale (8,310) — — — — — — (8,310) Earnings before income taxes $ 7,274 $ 7,770 $ 3,097 $ 5,836 $ — $ 16,703 $ (3,906) $ 20,071 Total assets $ 119,009 $ 96,472 $ 34,452 $ 59,086 $ — $ 190,010 $ (10,741) $ 298,278 Purchases of property, equipment and capitalized software 781 1,008 1,291 419 — 2,718 — 3,499 Depreciation and amortization 889 1,123 1,294 793 — 3,210 — 4,099 2023 Revenues - unaffiliated customers: Premiums $ 269,052 $ 21,775 $ — $ — $ — $ 21,775 $ — $ 290,827 Products — 207 162 42,214 — 42,583 — 42,583 Services 10,057 14,109 7,760 2,197 — 24,066 — 34,123 Total revenues - unaffiliated customers 279,109 36,091 7,922 44,411 — 88,424 — 367,533 Total revenues - affiliated customers — 57,696 10,896 71,484 (3,703) 136,373 (136,373) — Investment and other income 2,251 1,532 114 192 — 1,838 — 4,089 Total revenues $ 281,360 $ 95,319 $ 18,932 $ 116,087 $ (3,703) $ 226,635 $ (136,373) $ 371,622 Total operating costs (a) $ 264,945 $ 88,759 $ 14,664 $ 110,972 $ (3,703) $ 210,692 $ (136,373) $ 339,264 Earnings from operations $ 16,415 $ 6,560 $ 4,268 $ 5,115 $ — $ 15,943 $ — $ 32,358 Interest expense — — — — — — (3,246) (3,246) Earnings before income taxes $ 16,415 $ 6,560 $ 4,268 $ 5,115 $ — $ 15,943 $ (3,246) $ 29,112 Total assets $ 110,943 $ 89,432 $ 34,173 $ 51,266 $ — $ 174,871 $ (12,094) $ 273,720 Purchases of property, equipment and capitalized software 866 1,199 974 347 — 2,520 — 3,386 Depreciation and amortization 989 1,058 1,229 696 — 2,983 — 3,972 2022 Revenues - unaffiliated customers: Premiums $ 238,783 $ 18,374 $ — $ — $ — $ 18,374 $ — $ 257,157 Products — 72 180 37,172 — 37,424 — 37,424 Services 10,035 10,917 4,996 1,603 — 17,516 — 27,551 Total revenues - unaffiliated customers 248,818 29,363 5,176 38,775 — 73,314 — 322,132 Total revenues - affiliated customers — 40,883 9,288 60,936 (2,760) 108,347 (108,347) — Investment and other income 923 928 117 62 — 1,107 — 2,030 Total revenues $ 249,741 $ 71,174 $ 14,581 $ 99,773 $ (2,760) $ 182,768 $ (108,347) $ 324,162 Total operating costs (a) $ 235,362 $ 65,142 $ 10,993 $ 95,337 $ (2,760) $ 168,712 $ (108,347) $ 295,727 Earnings from operations $ 14,379 $ 6,032 $ 3,588 $ 4,436 $ — $ 14,056 $ — $ 28,435 Interest expense — — — — — — (2,092) (2,092) Earnings before income taxes $ 14,379 $ 6,032 $ 3,588 $ 4,436 $ — $ 14,056 $ (2,092) $ 26,343 Total assets $ 107,094 $ 68,950 $ 31,090 $ 47,476 $ — $ 147,516 $ (8,905) $ 245,705 Purchases of property, equipment and capitalized software 799 997 698 308 — 2,003 — 2,802 Depreciation and amortization 973 943 841 643 — 2,427 — 3,400 (a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each reportable segment.

Schedule I (Tables)

Schedule I (Tables)	12 Months Ended
	Dec. 31, 2024
Condensed Financial Statements, Captions [Line Items]
Schedule of Maturities of Long-term Debt [Table Text Block]	Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2025 $ 4,548 2026 3,756 2027 3,531 2028 3,106 2029 3,656 Thereafter 59,908
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Condensed Balance Sheet [Table Text Block]	Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Balance Sheets (in millions, except per share data) December 31, December 31, Assets Current assets: Cash and cash equivalents $ 234 $ 776 Other current assets 411 570 Total current assets 645 1,346 Equity in net assets of subsidiaries 179,209 153,692 Long-term notes receivable from subsidiaries 6,062 5,693 Other assets 920 831 Total assets $ 186,836 $ 161,562 Liabilities and shareholders’ equity Current liabilities: Accounts payable and accrued liabilities $ 1,501 $ 1,116 Short-term notes payable to subsidiaries 2,016 9,887 Short-term borrowings and current maturities of long-term debt 4,348 4,086 Total current liabilities 7,865 15,089 Long-term debt, less current maturities 71,831 57,387 Long-term notes payable to subsidiaries 14,405 — Other liabilities 77 330 Total liabilities 94,178 72,806 Commitments and contingencies (Note 4) Shareholders’ equity: Preferred stock, $0.001 par value -10 shares authorized; no shares issued or outstanding — — Common stock, $0.01 par value - 3,000 shares authorized; 915 and 924 issued and outstanding 9 9 Retained earnings 96,036 95,774 Accumulated other comprehensive loss (3,387) (7,027) Total UnitedHealth Group shareholders’ equity 92,658 88,756 Total liabilities and shareholders’ equity $ 186,836 $ 161,562
Condensed Statement of Comprehensive Income [Table Text Block]	Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Comprehensive Income For the Years Ended December 31, (in millions) 2024 2023 2022 Revenues: Investment and other income $ 368 $ 312 $ 255 Total revenues 368 312 255 Operating costs: Operating costs 108 35 121 Interest expense 4,544 3,469 2,110 Total operating costs 4,652 3,504 2,231 Loss before income taxes (4,284) (3,192) (1,976) Benefit for income taxes 1,032 654 429 Loss of parent company (3,252) (2,538) (1,547) Equity in undistributed income of subsidiaries 17,657 24,919 21,667 Net earnings 14,405 22,381 20,120 Other comprehensive income (loss) 3,640 1,366 (3,009) Comprehensive income $ 18,045 $ 23,747 $ 17,111
Condensed Cash Flow Statement [Table Text Block]	Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Cash Flows For the Years Ended December 31, (in millions) 2024 2023 2022 Operating activities Cash flows from operating activities $ 4,852 $ 17,443 $ 14,754 Investing activities Issuances of notes to subsidiaries (349) (41) (567) Repayments of notes to subsidiaries 225 817 281 Cash paid for acquisitions and other transactions (13,750) (8,144) (20,728) Return of capital to parent company 21 639 1,424 Capital contributions to subsidiaries — (2,472) (570) Cash received from dispositions, net 2,444 624 2,787 Other, net 30 286 — Cash flows used for investing activities (11,379) (8,291) (17,373) Financing activities Common stock repurchases (9,000) (8,000) (7,000) Proceeds from common stock issuances 1,846 1,353 1,253 Cash dividends paid (7,533) (6,761) (5,991) (Repayments of) proceeds from short-term borrowings, net (151) 11 732 Proceeds from issuance of long-term debt 17,811 6,394 14,819 Repayments of long-term debt (3,000) (2,125) (3,015) (Repayments of) proceeds from short-term notes from subsidiaries, net (7,966) 1,188 594 Proceeds from long-term notes from subsidiaries 14,396 — — Repayments of long-term notes from subsidiaries (28) — — Other, net (390) (702) (674) Cash flows from (used for) financing activities 5,985 (8,642) 718 (Decrease) increase in cash and cash equivalents (542) 510 (1,901) Cash and cash equivalents, beginning of period 776 266 2,167 Cash and cash equivalents, end of period $ 234 $ 776 $ 266 Supplemental cash flow disclosures Cash paid for interest $ 4,241 $ 3,257 $ 1,969 Cash paid for income taxes 2,450 4,426 4,298
Schedule of Maturities of Long-term Debt [Table Text Block]	Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2025 $ 4,350 2026 3,650 2027 3,425 2028 3,000 2029 3,550 Thereafter 59,802

Basis of Presentation, Uses o_4

Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivable, after Allowance for Credit Loss, Current	$ 22,365	$ 21,276
Revenue, Remaining Performance Obligation, Amount	12,700
Other current receivables	26,089	17,694
Inventory, Net	$ 3,800	2,800
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities
Accounts payable and accrued liabilities	$ 34,337	31,958
Other Liabilities, Current	$ 27,346	27,072
Number Of Days Notice Required To Cancel Health Insurance Contract	30 days
Goodwill, Impairment Loss	$ 0	0	$ 0
Impairment of Intangible Assets (Excluding Goodwill)	$ 0	0	$ 0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Percentage	50%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 years
Other Current Liabilities [Member]
Health savings account deposits	$ 13,700	13,500
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Plan Award, Options, Award Exercisable Period	10 years
Employee Stock Purchase Plan (ESPP) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	10%
Health Insurance Product Line [Member]
Short-duration Insurance Contracts, Historical Claims Duration, First 90 Days	0.90
Products and services [Member]
Accounts Receivable, after Allowance for Credit Loss, Current	$ 9,900	8,600
Pharmaceutical Manufacturer Rebates Receivable [Member]
Other current receivables	$ 12,500	$ 11,000

Basis of Presentation, Uses o_5

Basis of Presentation, Uses of Estimates and Significant Accounting Policies Useful lives for property, equipment and capitalized software (Details)	Dec. 31, 2024
Furniture, Fixtures and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Furniture, Fixtures and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Buildings [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	35 years
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	40 years
Capitalized software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Capitalized software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years

Basis of Presentation, Uses o_6

Basis of Presentation, Uses of Estimates and Significant Accounting Policies Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interest, beginning of period	$ 4,498
Acquisitions	26	$ 1,928	$ 374
Distributions	(744)	(516)	(387)
Fair value and other adjustments	53	201	(114)
Redeemable Noncontrolling Interest, end of period	4,323	4,498
Redeemable Noncontrolling Interests [Member]
Noncontrolling Interest [Line Items]
Net earnings	174	188
Acquisitions	33	122
Redemptions	(280)	(730)
Distributions	(125)	(144)
Fair value and other adjustments	23	165
Redeemable Noncontrolling Interests [Member]
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interest, beginning of period	4,498	4,897
Redeemable Noncontrolling Interest, end of period	$ 4,323	$ 4,498	$ 4,897

Investments (Narrative) (Detail

Investments (Narrative) (Details) $ in Billions	Dec. 31, 2024 USD ($) positions	Dec. 31, 2023 USD ($)
Investments [Abstract]
Equity Securities, FV-NI and without Readily Determinable Fair Value	$ 4.9	$ 4.9
Equity Method Investments	$ 3.8	$ 1.4
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | positions	34,000
Total number of security positions	43,000

Investments (Short-Term and Lon

Investments (Short-Term and Long-Term Investments) (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	$ 49,815	$ 47,451
Securities, Available for sale Debt Securities, Gross Unrealized Gains	62	134
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(2,958)	(2,690)
Debt Securities, Available-for-sale	46,919	44,895
Held-to-maturity securities, Amortized Cost	512	603
Securities, Held to maturity, Unrecognized Holding Gain	0	1
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(4)	(8)
Debt Securities, Held-to-maturity, Fair Value	508	596
Total investments, Amortized Cost	50,327	48,054
Total investments, Gross Unrealized Gains	62	135
Total investments, Gross Unrealized Losses	(2,962)	(2,698)
Investments, Fair Value Disclosure	47,427	45,491
Debt Securities - available-for-sale
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale	46,919	44,895
U.S. Government and Agency Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	4,600	4,674
Securities, Available for sale Debt Securities, Gross Unrealized Gains	1	3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(274)	(234)
Debt Securities, Available-for-sale	4,327	4,443
Held-to-maturity securities, Amortized Cost	444	506
Securities, Held to maturity, Unrecognized Holding Gain	0	1
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(2)	(6)
Debt Securities, Held-to-maturity, Fair Value	442	501
State and Municipal Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	7,357	7,636
Securities, Available for sale Debt Securities, Gross Unrealized Gains	2	39
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(375)	(322)
Debt Securities, Available-for-sale	6,984	7,353
Held-to-maturity securities, Amortized Cost	28	28
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(2)	(2)
Debt Securities, Held-to-maturity, Fair Value	26	26
Corporate Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	24,391	23,136
Securities, Available for sale Debt Securities, Gross Unrealized Gains	56	67
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(1,140)	(1,186)
Debt Securities, Available-for-sale	23,307	22,017
Held-to-maturity securities, Amortized Cost	40	69
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0	0
Debt Securities, Held-to-maturity, Fair Value	40	69
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	10,577	8,982
Securities, Available for sale Debt Securities, Gross Unrealized Gains	1	22
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(994)	(708)
Debt Securities, Available-for-sale	9,584	8,296
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	2,890	3,023
Securities, Available for sale Debt Securities, Gross Unrealized Gains	2	3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(175)	(240)
Debt Securities, Available-for-sale	$ 2,717	$ 2,786

Investments (Amortized Cost and

Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Schedule of Investments [Line Items]
Due in one year or less, Amortized Cost	$ 3,952
Due after one year through five years, Amortized Cost	14,845
Due after five years through ten years, Amortized Cost	12,110
Due after ten years, Amortized Cost	5,441
Total debt securities - available-for-sale, Amortized Cost	49,815	$ 47,451
Due in one year or less, Fair Value	3,932
Due after one year through five years, Fair Value	14,384
Due after five years through ten years, Fair Value	11,213
Due after ten years, Fair Value	5,089
Debt Securities, Available-for-sale	46,919	44,895
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost	320
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value	319
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost	161
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value	161
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost	14
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value	13
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after 10 Years, Amortized Cost	17
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value	15
Debt Securities, Held-to-maturity	512	603
Debt Securities, Held-to-maturity, Fair Value	508	596
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Mortgage-backed securities, Amortized Cost	10,577
Total debt securities - available-for-sale, Amortized Cost	10,577	8,982
Debt Securities, Available-for-sale	9,584	8,296
Mortgage-backed securities, Fair Value	9,584
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Mortgage-backed securities, Amortized Cost	2,890
Total debt securities - available-for-sale, Amortized Cost	2,890	3,023
Debt Securities, Available-for-sale	2,717	$ 2,786
Mortgage-backed securities, Fair Value	$ 2,717

Investments (Fair Value of Avai

Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt Securities - available-for-sale
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	$ 16,677	$ 5,619
Less Than 12 Months, Gross Unrealized Losses	(518)	(49)
Greater Than 12 Months, Fair Value	24,223	28,107
Greater Than 12 Months, Gross Unrealized Losses	(2,440)	(2,641)
Total, Fair Value	40,900	33,726
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	(2,958)	(2,690)
U.S. Government and Agency Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	1,475	1,270
Less Than 12 Months, Gross Unrealized Losses	(51)	(7)
Greater Than 12 Months, Fair Value	2,152	2,077
Greater Than 12 Months, Gross Unrealized Losses	(223)	(227)
Total, Fair Value	3,627	3,347
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	(274)	(234)
State and Municipal Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	2,593	907
Less Than 12 Months, Gross Unrealized Losses	(58)	(7)
Greater Than 12 Months, Fair Value	4,085	4,063
Greater Than 12 Months, Gross Unrealized Losses	(317)	(315)
Total, Fair Value	6,678	4,970
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	(375)	(322)
Corporate Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	7,402	1,826
Less Than 12 Months, Gross Unrealized Losses	(213)	(17)
Greater Than 12 Months, Fair Value	11,449	14,696
Greater Than 12 Months, Gross Unrealized Losses	(927)	(1,169)
Total, Fair Value	18,851	16,522
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	(1,140)	(1,186)
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	4,791	1,337
Less Than 12 Months, Gross Unrealized Losses	(191)	(12)
Greater Than 12 Months, Fair Value	4,674	5,069
Greater Than 12 Months, Gross Unrealized Losses	(803)	(696)
Total, Fair Value	9,465	6,406
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	(994)	(708)
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	416	279
Less Than 12 Months, Gross Unrealized Losses	(5)	(6)
Greater Than 12 Months, Fair Value	1,863	2,202
Greater Than 12 Months, Gross Unrealized Losses	(170)	(234)
Total, Fair Value	2,279	2,481
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	$ (175)	$ (240)

Fair Value (Narrative) (Details

Fair Value (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value [Line Items]
Transfers Into Level 3	$ 0	$ 0
Transfers out of Level 3	0	0
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount	710	276	$ 211
Fair Value, Nonrecurring [Member]
Fair Value [Line Items]
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis	$ 0	$ 0	$ 0

Fair Value (Financial Assets an

Fair Value (Financial Assets and Liabilities, Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 25,312	$ 25,427
Debt Securities, Available-for-sale	46,919	44,895
Equity Securities, FV-NI	1,948	2,553
Assets under management	0	3,755
Assets, Fair Value Disclosure	74,179	76,630
Debt Securities - available-for-sale
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	46,919	44,895
U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,327	4,443
State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	6,984	7,353
Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	23,307	22,017
U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	9,584	8,296
Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	2,717	2,786
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	25,248	25,345
Equity Securities, FV-NI	1,859	2,468
Assets under management		1,505
Assets, Fair Value Disclosure	31,330	33,500
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities - available-for-sale
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,223	4,182
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,194	4,167
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	29	15
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	64	82
Equity Securities, FV-NI	24	16
Assets under management		2,140
Assets, Fair Value Disclosure	42,347	42,749
Other Observable Inputs (Level 2) [Member] | Debt Securities - available-for-sale
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	42,259	40,511
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	133	276
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	6,984	7,353
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	22,841	21,800
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	9,584	8,296
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	2,717	2,786
Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Equity Securities, FV-NI	65	69
Assets under management		110
Assets, Fair Value Disclosure	502	381
Unobservable Inputs (Level 3) [Member] | Debt Securities - available-for-sale
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	437	202
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	437	202
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	$ 0	$ 0

Fair Value (Financial Assets _2

Fair Value (Financial Assets and Liabilities, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	$ 508	$ 596
Debt Securities, Held-to-maturity	512	603
Debt and other financing obligations, carrying value	76,180	61,473
Long-term debt and other financing obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt and other financing obligations, carrying value	75,604	61,449
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	508	596
Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	482	524
Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	26	72
Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	0	0
Long-term debt and other financing obligations [Member] | Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt and other financing obligations	70,565	59,851
Long-term debt and other financing obligations [Member] | Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt and other financing obligations	0	0
Long-term debt and other financing obligations [Member] | Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt and other financing obligations	70,565	59,851
Long-term debt and other financing obligations [Member] | Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt and other financing obligations	$ 0	$ 0

Property, Plant, and Capitali_3

Property, Plant, and Capitalized Software (Narrative) (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation	$ 1	$ 1.1	$ 1.1
Capitalized Computer Software, Amortization	$ 1.4	$ 1.2	$ 1

Property, Plant, and Capitali_4

Property, Plant, and Capitalized Software Property Plant and Equipment Table (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Land and improvements	$ 364	$ 712
Buildings and improvements	4,215	5,573
Computer equipment	2,267	2,007
Furniture and fixtures	1,694	2,375
Less accumulated depreciation	(3,645)	(4,210)
Property and equipment, net	4,895	6,457
Capitalized software	8,984	7,822
Less accumulated amortization	(3,326)	(2,829)
Capitalized software, net	5,658	4,993
Total property, equipment and capitalized software, net	$ 10,553	$ 11,450

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 1.7	$ 1.6	$ 1.3

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets Changes in the Carrying Amount of Goodwill by Reporting Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Line Items]
Goodwill, Beginning Balance	$ 103,732	$ 93,352
Acquisitions	4,376	10,121
Dispositions, foreign currency effects and adjustments, net	(1,374)	259
Goodwill, Ending Balance	106,734	103,732
UnitedHealthcare
Goodwill [Line Items]
Goodwill, Beginning Balance	27,878	27,395
Acquisitions	0	296
Dispositions, foreign currency effects and adjustments, net	(717)	187
Goodwill, Ending Balance	27,161	27,878
Optum Health
Goodwill [Line Items]
Goodwill, Beginning Balance	37,079	29,238
Acquisitions	2,071	8,023
Dispositions, foreign currency effects and adjustments, net	(324)	(182)
Goodwill, Ending Balance	38,826	37,079
Optum Insight
Goodwill [Line Items]
Goodwill, Beginning Balance	19,307	17,244
Acquisitions	0	1,802
Dispositions, foreign currency effects and adjustments, net	(327)	261
Goodwill, Ending Balance	18,980	19,307
Optum Rx
Goodwill [Line Items]
Goodwill, Beginning Balance	19,468	19,475
Acquisitions	2,305	0
Dispositions, foreign currency effects and adjustments, net	(6)	(7)
Goodwill, Ending Balance	$ 21,767	$ 19,468

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets Gross carrying value, accumulated amortization and net carrying value of intangible assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 31,618	$ 22,473
Intangible Assets, Accumulated Amortization	(8,350)	(7,279)
Intangible Assets, Net (Excluding Goodwill)	23,268	15,194
Customer-Related Intangible Assets [Member]
Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	17,190	16,636
Intangible Assets, Accumulated Amortization	(6,675)	(5,909)
Intangible Assets, Net (Excluding Goodwill)	10,515	10,727
Trademarks and Technology [Member]
Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	2,917	2,508
Intangible Assets, Accumulated Amortization	(1,284)	(958)
Intangible Assets, Net (Excluding Goodwill)	1,633	1,550
Operating licenses and certificates, trademarks, and other indefinite-lived [Member]
Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	10,454	2,116
Intangible Assets, Accumulated Amortization	0	0
Intangible Assets, Net (Excluding Goodwill)	10,454	2,116
Other Intangible Assets [Member]
Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	1,057	1,213
Intangible Assets, Accumulated Amortization	(391)	(412)
Intangible Assets, Net (Excluding Goodwill)	$ 666	$ 801

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets Weighted-average useful lives assigned to intangible assets acquired in business combinations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 1,807	$ 747
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years	9 years
Indefinite-Lived Intangible Assets Acquired	$ 8,795	$ 1,427
Acquired intangible assets	10,602	2,174
Customer-Related Intangible Assets [Member]
Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 1,258	$ 477
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years	12 years
Trademarks and Technology [Member]
Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 527	$ 226
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	6 years	5 years
Other Intangible Assets [Member]
Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 22	$ 44
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	8 years	9 years

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets Amortization Expense relating to Intangible Assets (Details) $ in Millions	Dec. 31, 2024 USD ($)
Intangible Assets [Line Items]
2025	$ 1,655
2026	1,503
2027	1,424
2028	1,344
2029	$ 1,211

Medical Costs Payable (Narrativ

Medical Costs Payable (Narrative) (Details) - USD ($) $ in Billions	Dec. 31, 2024	Dec. 31, 2023
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount	$ 23.7	$ 22.3

Medical Costs Payable Rollforwa

Medical Costs Payable Rollforward (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]
Medical costs payable, beginning of period	$ 32,395	$ 29,056	$ 24,483
Acquisitions (dispositions), net	(755)	1	308
Reported medical costs:
Current year	264,885	242,734	211,252
Prior years	(700)	(840)	(410)
Total reported medical costs	264,185	241,894	210,842
Medical payments:
Payments for current year	(231,890)	(211,380)	(184,049)
Payments for prior years	(29,532)	(27,176)	(22,528)
Total medical payments	(261,422)	(238,556)	(206,577)
Medical costs payable included within businesses held for sale	(179)	0	0
Medical costs payable, end of period	$ 34,224	$ 32,395	$ 29,056

Medical Costs Payable, Incurred

Medical Costs Payable, Incurred and Paid Medical Cost Development (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Acquisitions (dispositions), net	$ (755)
Medical costs payable included within businesses held for sale	(179)	$ 0	$ 0
Health Insurance Product Line [Member]
Net Incurred Medical Costs	507,041
Net Cumulative Medical Payments	(472,002)
Net remaining outstanding liabilities prior to 2023	119
Total Medical costs payable	34,224
Health Insurance Product Line [Member] | Short-duration Insurance Contracts, Accident Year 2023 [Member]
Net Incurred Medical Costs	242,156	242,734
Net Cumulative Medical Payments	(240,112)	$ (211,380)
Health Insurance Product Line [Member] | Short-duration Insurance Contracts, Accident Year 2024 [Member]
Net Incurred Medical Costs	264,885
Net Cumulative Medical Payments	$ (231,890)

Short-Term Borrowings and Lon_3

Short-Term Borrowings and Long-Term Debt (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	4.90%
Maximum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	7.50%
Commercial Paper [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	4.40%
364 Day $7.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit, Credit Facility, Maximum Borrowing Capacity	$ 7,000
Line of Credit Facility, Expiration Period	364 days
Three Year $7.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit, Credit Facility, Maximum Borrowing Capacity	$ 7,000
Line of Credit Facility, Expiration Period	3 years
Five Year $7.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit, Credit Facility, Maximum Borrowing Capacity	$ 7,000
Line of Credit Facility, Expiration Period	5 years
Subsidiaries [Member]
Debt Instrument [Line Items]
Other Long-term Debt	$ 700	$ 1,100
Other Long-term Debt, Current	$ 197	$ 188

Short-Term Borrowings and Lon_4

Short-Term Borrowings and Long-Term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Carrying Value	$ 76,180	$ 61,473
Commercial Paper [Member]
Debt Instrument [Line Items]
Commercial Paper	1,300	1,088
3.500% notes due February 2024 [Member]
Debt Instrument [Line Items]
Par Value	$ 750
Debt Instrument, Interest Rate, Stated Percentage	3.50%
Unsecured Debt, Current	$ 0	750
0.550% notes due May 2024 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	0.55%
Unsecured Debt, Current	$ 0	999
2.375% notes due August 2024 [Member]
Debt Instrument [Line Items]
Par Value	$ 750
Debt Instrument, Interest Rate, Stated Percentage	2.375%
Unsecured Debt, Current	$ 0	750
5.000% notes due October 2024 [Member]
Debt Instrument [Line Items]
Par Value	$ 500
Debt Instrument, Interest Rate, Stated Percentage	5%
Unsecured Debt, Current	$ 0	499
3.750% Notes Due July 2025 [Member]
Debt Instrument [Line Items]
Par Value	$ 2,000
Debt Instrument, Interest Rate, Stated Percentage	3.75%
Unsecured Debt, Current	$ 1,999
Unsecured Long-term Debt, Noncurrent		1,997
5.150% notes due October 2025 [Member]
Debt Instrument [Line Items]
Par Value	$ 750
Debt Instrument, Interest Rate, Stated Percentage	5.15%
Unsecured Debt, Current	$ 749
Unsecured Long-term Debt, Noncurrent		748
3.700% notes due December 2025 [Member]
Debt Instrument [Line Items]
Par Value	$ 300
Debt Instrument, Interest Rate, Stated Percentage	3.70%
Unsecured Debt, Current	$ 300
Unsecured Long-term Debt, Noncurrent		299
1.250% notes due January 2026 [Member]
Debt Instrument [Line Items]
Par Value	$ 500
Debt Instrument, Interest Rate, Stated Percentage	1.25%
Unsecured Long-term Debt, Noncurrent	$ 499	498
3.100% notes due March 2026 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	3.10%
Unsecured Long-term Debt, Noncurrent	$ 999	998
1.150% notes due May 2026 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	1.15%
Unsecured Long-term Debt, Noncurrent	$ 953	924
Floating Rate Notes Due July 2026
Debt Instrument [Line Items]
Par Value	500
Unsecured Long-term Debt, Noncurrent	499	0
4.750% notes due July 2026
Debt Instrument [Line Items]
Par Value	$ 650
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Unsecured Long-term Debt, Noncurrent	$ 648	0
3.450% notes due January 2027 [Member]
Debt Instrument [Line Items]
Par Value	$ 750
Debt Instrument, Interest Rate, Stated Percentage	3.45%
Unsecured Long-term Debt, Noncurrent	$ 749	748
4.600% notes due April 2027
Debt Instrument [Line Items]
Par Value	$ 500
Debt Instrument, Interest Rate, Stated Percentage	4.60%
Unsecured Long-term Debt, Noncurrent	$ 496	0
3.375% notes due April 2027 [Member]
Debt Instrument [Line Items]
Par Value	$ 625
Debt Instrument, Interest Rate, Stated Percentage	3.375%
Unsecured Long-term Debt, Noncurrent	$ 623	622
3.700% notes due May 2027 [Member]
Debt Instrument [Line Items]
Par Value	$ 600
Debt Instrument, Interest Rate, Stated Percentage	3.70%
Unsecured Long-term Debt, Noncurrent	$ 598	598
2.950% notes due October 2027 [Member]
Debt Instrument [Line Items]
Par Value	$ 950
Debt Instrument, Interest Rate, Stated Percentage	2.95%
Unsecured Long-term Debt, Noncurrent	$ 946	944
5.250% notes due February 2028 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	5.25%
Unsecured Long-term Debt, Noncurrent	$ 998	1,011
3.850% notes due June 2028 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,150
Debt Instrument, Interest Rate, Stated Percentage	3.85%
Unsecured Long-term Debt, Noncurrent	$ 1,147	1,146
3.875% notes due December 2028 [Member]
Debt Instrument [Line Items]
Par Value	$ 850
Debt Instrument, Interest Rate, Stated Percentage	3.875%
Unsecured Long-term Debt, Noncurrent	$ 847	846
4.250% notes due January 2029
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Unsecured Long-term Debt, Noncurrent	$ 1,221	1,238
4.700% notes due April 2029
Debt Instrument [Line Items]
Par Value	$ 400
Debt Instrument, Interest Rate, Stated Percentage	4.70%
Unsecured Long-term Debt, Noncurrent	$ 398	0
4.000% notes due May 2029 [Member]
Debt Instrument [Line Items]
Par Value	$ 900
Debt Instrument, Interest Rate, Stated Percentage	4%
Unsecured Long-term Debt, Noncurrent	$ 854	862
2.875% notes due August 2029 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	2.875%
Unsecured Long-term Debt, Noncurrent	$ 902	908
4.800% notes due January 2030
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	4.80%
Unsecured Long-term Debt, Noncurrent	$ 1,225	0
5.300% notes due February 2030 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	5.30%
Unsecured Long-term Debt, Noncurrent	$ 1,243	1,275
2.000% notes due May 2030 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	2%
Unsecured Long-term Debt, Noncurrent	$ 1,240	1,238
4.900% notes due April 2031
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	4.90%
Unsecured Long-term Debt, Noncurrent	$ 982	0
2.300% notes due May 2031 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,500
Debt Instrument, Interest Rate, Stated Percentage	2.30%
Unsecured Long-term Debt, Noncurrent	$ 1,271	1,290
4.950% notes due January 2032
Debt Instrument [Line Items]
Par Value	$ 1,500
Debt Instrument, Interest Rate, Stated Percentage	4.95%
Unsecured Long-term Debt, Noncurrent	$ 1,489	0
4.200% notes due May 2032 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,500
Debt Instrument, Interest Rate, Stated Percentage	4.20%
Unsecured Long-term Debt, Noncurrent	$ 1,372	1,412
5.350% notes due February 2033 [Member]
Debt Instrument [Line Items]
Par Value	$ 2,000
Debt Instrument, Interest Rate, Stated Percentage	5.35%
Unsecured Long-term Debt, Noncurrent	$ 1,966	2,046
4.500% notes due April 2033
Debt Instrument [Line Items]
Par Value	$ 1,500
Debt Instrument, Interest Rate, Stated Percentage	4.50%
Unsecured Long-term Debt, Noncurrent	$ 1,410	1,463
5.000% notes due April 2034
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	5%
Unsecured Long-term Debt, Noncurrent	$ 1,214	0
5.150% notes due July 2034
Debt Instrument [Line Items]
Par Value	$ 2,000
Debt Instrument, Interest Rate, Stated Percentage	5.15%
Unsecured Long-term Debt, Noncurrent	$ 1,959	0
4.625% notes Due July 2035 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	4.625%
Unsecured Long-term Debt, Noncurrent	$ 971	1,014
5.800% notes Due March 2036 [Member]
Debt Instrument [Line Items]
Par Value	$ 850
Debt Instrument, Interest Rate, Stated Percentage	5.80%
Unsecured Long-term Debt, Noncurrent	$ 838	838
6.500% notes Due June 2037 [Member]
Debt Instrument [Line Items]
Par Value	$ 500
Debt Instrument, Interest Rate, Stated Percentage	6.50%
Unsecured Long-term Debt, Noncurrent	$ 492	491
6.625% notes due November 2037 [Member]
Debt Instrument [Line Items]
Par Value	$ 650
Debt Instrument, Interest Rate, Stated Percentage	6.625%
Unsecured Long-term Debt, Noncurrent	$ 641	640
6.875% notes Due Februray 2038 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,100
Debt Instrument, Interest Rate, Stated Percentage	6.875%
Unsecured Long-term Debt, Noncurrent	$ 1,079	1,078
3.500% notes due August 2039 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	3.50%
Unsecured Long-term Debt, Noncurrent	$ 1,243	1,242
2.750% notes due May 2040 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	2.75%
Unsecured Long-term Debt, Noncurrent	$ 970	968
5.700% notes Due October 2040 [Member]
Debt Instrument [Line Items]
Par Value	$ 300
Debt Instrument, Interest Rate, Stated Percentage	5.70%
Unsecured Long-term Debt, Noncurrent	$ 296	296
5.950% notes Due Februrary 2041 [Member]
Debt Instrument [Line Items]
Par Value	$ 350
Debt Instrument, Interest Rate, Stated Percentage	5.95%
Unsecured Long-term Debt, Noncurrent	$ 346	346
3.050% notes due May 2041 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,500
Debt Instrument, Interest Rate, Stated Percentage	3.05%
Unsecured Long-term Debt, Noncurrent	$ 1,485	1,484
4.625% notes Due November 2041 [Member]
Debt Instrument [Line Items]
Par Value	$ 600
Debt Instrument, Interest Rate, Stated Percentage	4.625%
Unsecured Long-term Debt, Noncurrent	$ 590	590
4.375% notes Due March 2042 [Member]
Debt Instrument [Line Items]
Par Value	$ 502
Debt Instrument, Interest Rate, Stated Percentage	4.375%
Unsecured Long-term Debt, Noncurrent	$ 487	486
3.950% notes Due October 2042 [Member]
Debt Instrument [Line Items]
Par Value	$ 625
Debt Instrument, Interest Rate, Stated Percentage	3.95%
Unsecured Long-term Debt, Noncurrent	$ 610	609
4.250% notes Due March 2043 [Member]
Debt Instrument [Line Items]
Par Value	$ 750
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Unsecured Long-term Debt, Noncurrent	$ 737	736
5.500% notes due July 2044
Debt Instrument [Line Items]
Par Value	$ 1,500
Debt Instrument, Interest Rate, Stated Percentage	5.50%
Unsecured Long-term Debt, Noncurrent	$ 1,475	0
4.750% notes Due July 2045 [Member]
Debt Instrument [Line Items]
Par Value	$ 2,000
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Unsecured Long-term Debt, Noncurrent	$ 1,976	1,975
4.200% notes due January 2047 [Member]
Debt Instrument [Line Items]
Par Value	$ 750
Debt Instrument, Interest Rate, Stated Percentage	4.20%
Unsecured Long-term Debt, Noncurrent	$ 739	739
4.250% notes due April 2047 [Member]
Debt Instrument [Line Items]
Par Value	$ 725
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Unsecured Long-term Debt, Noncurrent	$ 718	718
3.750% notes due October 2047 [Member]
Debt Instrument [Line Items]
Par Value	$ 950
Debt Instrument, Interest Rate, Stated Percentage	3.75%
Unsecured Long-term Debt, Noncurrent	$ 935	935
4.250% notes due June 2048 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,350
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Unsecured Long-term Debt, Noncurrent	$ 1,332	1,331
4.450% notes due December 2048 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,100
Debt Instrument, Interest Rate, Stated Percentage	4.45%
Unsecured Long-term Debt, Noncurrent	$ 1,087	1,087
3.700% notes due August 2049 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	3.70%
Unsecured Long-term Debt, Noncurrent	$ 1,237	1,236
2.900% notes due May 2050 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	2.90%
Unsecured Long-term Debt, Noncurrent	$ 1,212	1,211
3.250% notes due May 2051 [Member]
Debt Instrument [Line Items]
Par Value	$ 2,000
Debt Instrument, Interest Rate, Stated Percentage	3.25%
Unsecured Long-term Debt, Noncurrent	$ 1,972	1,972
4.750% notes due May 2052 [Member]
Debt Instrument [Line Items]
Par Value	$ 2,000
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Unsecured Long-term Debt, Noncurrent	$ 1,966	1,966
5.875% notes due February 2053 [Member]
Debt Instrument [Line Items]
Par Value	$ 2,000
Debt Instrument, Interest Rate, Stated Percentage	5.875%
Unsecured Long-term Debt, Noncurrent	$ 1,968	1,968
5.050% notes due April 2053
Debt Instrument [Line Items]
Par Value	$ 2,000
Debt Instrument, Interest Rate, Stated Percentage	5.05%
Unsecured Long-term Debt, Noncurrent	$ 1,969	1,969
5.375% Notes due April 2054
Debt Instrument [Line Items]
Par Value	$ 1,750
Debt Instrument, Interest Rate, Stated Percentage	5.375%
Unsecured Long-term Debt, Noncurrent	$ 1,729	0
5.625% notes due July 2054
Debt Instrument [Line Items]
Par Value	$ 2,750
Debt Instrument, Interest Rate, Stated Percentage	5.625%
Unsecured Long-term Debt, Noncurrent	$ 2,724	0
3.875% notes due August 2059 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,250
Debt Instrument, Interest Rate, Stated Percentage	3.875%
Unsecured Long-term Debt, Noncurrent	$ 1,229	1,229
3.125% notes due May 2060 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	3.125%
Unsecured Long-term Debt, Noncurrent	$ 967	966
4.950% notes due May 2062 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,000
Debt Instrument, Interest Rate, Stated Percentage	4.95%
Unsecured Long-term Debt, Noncurrent	$ 981	981
6.050% notes due February 2063 [Member]
Debt Instrument [Line Items]
Par Value	$ 1,500
Debt Instrument, Interest Rate, Stated Percentage	6.05%
Unsecured Long-term Debt, Noncurrent	$ 1,466	1,466
5.200% notes due April 2063
Debt Instrument [Line Items]
Par Value	$ 1,750
Debt Instrument, Interest Rate, Stated Percentage	5.20%
Unsecured Long-term Debt, Noncurrent	$ 1,710	1,709
5.500% Notes due April 2064
Debt Instrument [Line Items]
Par Value	$ 1,100
Debt Instrument, Interest Rate, Stated Percentage	5.50%
Unsecured Long-term Debt, Noncurrent	$ 1,085	0
5.750% notes due July 2064
Debt Instrument [Line Items]
Par Value	$ 1,850
Debt Instrument, Interest Rate, Stated Percentage	5.75%
Unsecured Long-term Debt, Noncurrent	$ 1,822	$ 0

Short-Term Borrowings and Lon_5

Short-Term Borrowings and Long-Term Debt Maturities of commercial paper and long-term debt (Details) $ in Millions	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
2025	$ 4,548
2026	3,756
2027	3,531
2028	3,106
2029	3,656
Thereafter	$ 59,908

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Decrease in Unrecognized Tax Benefits is Reasonably Possible	$ 101
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	210	$ 177	$ 64
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	637	$ 430
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 2,000
Federal [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Description	indefinite
Earliest Tax Year [Member] | State [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Expiration Date	Jan. 01, 2025
Latest Tax Year [Member] | State [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Expiration Date	Jan. 01, 2044

Income before income taxes (Det

Income before income taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax [Abstract]
Domestic	$ 28,264	$ 29,210	$ 26,685
Foreign	(8,193)	(98)	(342)
Earnings before income taxes	$ 20,071	$ 29,112	$ 26,343

Income Taxes Reconciliation of

Income Taxes Reconciliation of Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current Provision:
Federal	$ 3,453	$ 4,418	$ 4,842
State and local	416	716	855
Foreign	1,256	1,079	680
Total current provision	5,125	6,213	6,377
Deferred benefit	(296)	(245)	(673)
Provision for income taxes, Amount	$ 4,829	$ 5,968	$ 5,704

Income Tax Reconciliation of th

Income Tax Reconciliation of the tax provision at the U.S. Federal Statutory Rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Tax provision at the U.S. federal statutory rate, Amount	$ 4,215	$ 6,114	$ 5,532
Tax provision at the U.S. federal statutory rate, Percent	21%	21%	21%
State income taxes, net of federal benefit, Amount	$ 343	$ 567	$ 621
State income taxes, net of federal benefit, Percent	1.70%	2%	2.40%
Share-based awards - excess tax benefit, Amount	$ (96)	$ (75)	$ (110)
Share-based awards - excess tax benefit, Percent	(0.50%)	(0.30%)	(0.40%)
Non-deductible compensation, Amount	$ 171	$ 174	$ 150
Non-deductible compensation, Percent	0.90%	0.60%	0.60%
Foreign rate differential, Amount	$ (369)	$ (442)	$ (265)
Foreign rate differential, Percent	(1.80%)	(1.50%)	(1.00%)
Tax effect of dispositions and other strategic transactions, Amount	$ 1,215	$ (29)	$ (215)
Tax effect of dispositions and other strategic transactions, Percent	6.10%	(0.10%)	(0.80%)
Other, net, Amount	$ (650)	$ (341)	$ (9)
Other, net, Percent	(3.30%)	(1.20%)	(0.10%)
Provision for income taxes, Amount	$ 4,829	$ 5,968	$ 5,704
Provision for income taxes, Percent	24.10%	20.50%	21.70%

Income Taxes Components of Defe

Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Deferred income tax assets:
Accrued expenses and allowances	$ 1,055	$ 754
U.S. federal and state net operating loss carryforwards	442	417
Share-based compensation	189	173
Nondeductible liabilities	343	329
Non-U.S. tax loss carryforwards	21	1,061
Lease liability	846	930
Net unrealized losses on investments	669	586
Other-domestic	597	327
Other-non-U.S.	59	484
Subtotal	4,221	5,061
Less: valuation allowances	(397)	(366)
Total deferred income tax assets	3,824	4,695
Deferred income tax liabilities:
U.S. federal and state intangible assets	(4,479)	(3,712)
Non-U.S. goodwill and intangible assets	(82)	(731)
Capitalized software	(288)	(415)
Depreciation and amortization	(400)	(371)
Prepaid expenses	(374)	(326)
Outside basis in partnerships	(960)	(811)
Lease right-of-use asset	(833)	(914)
Other-non-U.S.	(28)	(436)
Total deferred income tax liabilities	(7,444)	(7,716)
Net deferred income tax liabilities	$ (3,620)	$ (3,021)

Income Taxes Reconciliation o_2

Income Taxes Reconciliation of the beginning and ending amount of unrecognized tax benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Gross unrecognized tax benefits, beginning of period	$ 3,716	$ 3,081	$ 2,310
Current year tax positions	578	782	586
Prior year tax positions, gross increases	10	97	206
Prior year tax positions, gross decreases	(121)	(212)	(21)
Statute of limitations lapses and settlements	(60)	(32)	0
Gross unrecognized tax benefits, end of period	$ 4,123	$ 3,716	$ 3,081

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - USD ($) shares in Millions, $ in Billions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Jun. 01, 2024
Shareholders' Equity Disclosure [Line Items]
Cash Dividends Paid to Parent, Consolidated Subsidiaries	$ 9.2	$ 8
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	37.8
Statutory Accounting Practices, Statutory Capital and Surplus Required	20.4
Share Repurchase Program, Authorized, Number of Shares			35
Extraordinary Dividends [Member]
Shareholders' Equity Disclosure [Line Items]
Cash Dividends Paid to Parent, Consolidated Subsidiaries	$ 2.6	$ 4.9

Shareholders' Equity Share Repu

Shareholders' Equity Share Repurchases (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Statement of Stockholders' Equity [Abstract]
Common shares repurchases, shares	17,000,000	16,000,000
Common share repurchases, average price per share	$ 529.85	$ 493.79
Common share repurchases, aggregate cost	$ 8,942	$ 8,000
Board authorized shares remaining	33,000,000	15,000,000

Shareholders' Equity Dividends

Shareholders' Equity Dividends (Details) - USD ($) $ / shares in Units, $ in Millions					12 Months Ended
	Dec. 17, 2024	Sep. 24, 2024	Jun. 25, 2024	Mar. 19, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Cash dividends per common share	$ 2.10	$ 2.10	$ 2.10	$ 1.88	$ 8.18	$ 7.29	$ 6.40
Payments of Ordinary Dividends, Common Stock	$ 1,932	$ 1,937	$ 1,935	$ 1,729	$ 7,533	$ 6,761	$ 5,991

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) shares in Millions, $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	48
Deferred Compensation, Recorded Liability	$ 2,100	$ 1,900
Employee Stock Purchase Plan (ESPP) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	16

Share-Based Compensation (Stock

Share-Based Compensation (Stock Option Activity) (Details) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at the beginning of the period | shares	21
Granted | shares	3
Exercised | shares	(6)
Forfeitures | shares	(1)
Outstanding at the end of the period | shares	17
Exercisable at end of period | shares	10
Vested and expected to vest, end of period | shares	17
Outstanding at beginning of period, Weighted-Average Exercise Price | $ / shares	$ 320
Granted, Weighted-Average Exercise Price | $ / shares	522
Exercised, Weighted-Average Exercise Price | $ / shares	253
Forfeitures, Weighted Average Exercise Price | $ / shares	480
Outstanding at end of period, Weighted-Average Exercise Price | $ / shares	370
Exercisable at end of period, Weighted-Average Exercise Price | $ / shares	298
Vested and expected to vest end of period, Weighted-Average Exercise Price | $ / shares	$ 368
Outstanding at end of period, Weighted Average Remaining Contractual Term (in years)	5 years 7 months 6 days
Exercisable at end of period, Weighted Average Remaining Contractual Term (in years)	4 years 2 months 12 days
Vested and expected to vest end of period, Weighted Average Remaining Contractual Term (in years)	5 years 6 months
Outstanding at end of period, Aggregate Intrinsic Value | $	$ 2,338
Exercisable at end of period, Aggregate Intrinsic Value | $	2,115
Vested and expected to vest end of period, Aggregate Intrinsic Value | $	$ 2,335

Share-Based Compensation (Restr

Share-Based Compensation (Restricted Share Activity) (Details) - Restricted Stock [Member] shares in Millions	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested at beginning of period | shares	4
Granted | shares	2
Vested | shares	(2)
Nonvested at end of period | shares	4
Nonvested at beginning of period, Weighted-Average Grant Date Fair Value per Share | $ / shares	$ 449
Weighted-average grant date fair value per share | $ / shares	523
Vested, Weighted Average Grant Date Fair Value per share | $ / shares	435
Nonvested at end of period, Weighted-Average Grant Date Fair Value per Share | $ / shares	$ 489

Share-Based Compensation Other

Share-Based Compensation Other Share-Based Compensation Data (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense, before tax	$ 1,018	$ 1,059	$ 925
Share-based compensation expense, net of tax effects	896	937	836
Income tax benefit realized from share-based award exercises	216	$ 231	$ 207
Unrecognized compensation expense related to share awards	$ 1,099
Weighted-average years to recognize compensation expense	1 year 3 months 18 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of shares granted, per share	$ 138	$ 134	$ 116
Total intrinsic value of stock options exercised	$ 1,886	$ 1,325	$ 1,419
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value per share	$ 523	$ 493	$ 483
Total fair value of restricted shares vested	$ 690	$ 803	$ 760
Employee Stock Purchase Plan (ESPP) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased	1	1	1

Share-Based Compensation (Share

Share-Based Compensation (Share-Based Compensation Principal Fair Value Assumptions) (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeiture rate	5%	5%	5%
Expected Life in years	4 years 7 months 6 days	4 years 7 months 6 days	4 years 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	5 years 6 months
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	3.60%	3.80%	1.90%
Expected Volatility	25.50%	29.70%	30.60%
Expected dividend yield	1.40%	1.30%	1.20%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	4.40%	4.60%	4.30%
Expected Volatility	30.70%	30.60%	30.80%
Expected dividend yield	1.50%	1.50%	1.20%

Commitments and Contingencies_3

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Operating Lease, Cost	$ 1,400	$ 1,400	$ 1,300
Operating Lease, Payments	$ 1,100	$ 1,100	$ 1,000
Operating Lease, Weighted Average Remaining Lease Term	9 years 6 months
Operating Lease, Weighted Average Discount Rate, Percent	4.70%
Other Commitment	$ 4,000
Other Commitments, Description	As of December 31, 2024, the Company has entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $4 billion.

Commitment and Contingencies Fu

Commitment and Contingencies Future Lease Payments (Details) $ in Millions	Dec. 31, 2024 USD ($)
Operating Leased Assets [Line Items]
2025	$ 1,014
2026	876
2027	688
2028	568
2029	583
Thereafter	2,465
Total future minimum lease payments	6,194
Less imputed interest	(1,305)
Total	$ 4,889

Dispositions and Held for Sal_3

Dispositions and Held for Sale (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Feb. 06, 2024
Disposition and Held for Sale [Line Items]
Loss on sale of subsidiary and subsidiaries held for sale	$ (8,310)	$ 0	$ 0
Gains on dispositions and other strategic transactions	3,333	489	$ 588
Equity Method Investments	3,800	$ 1,400
Brazil Disposal Group
Disposition and Held for Sale [Line Items]
Foreign Currency Translation Loss	(4,100)
Loss on sale of subsidiary and subsidiaries held for sale	(7,100)
Total assets				$ 4,924
Businesses Held for Sale
Disposition and Held for Sale [Line Items]
Loss on sale of subsidiary and subsidiaries held for sale	(1,200)
Foreign currency translation loss	(855)
Total assets	894
Dispositions and other Strategic Transactions
Disposition and Held for Sale [Line Items]
Noncash or Part Noncash Divestiture, Amount of Consideration Received	3,000
Equity Method Investments	1,900
Total assets	1,000
Future Repurchase Obligations	3,400
Put and Call Options	630
Dispositions and other Strategic Transactions | Operating Expense
Disposition and Held for Sale [Line Items]
Gains on dispositions and other strategic transactions	3,300
Dispositions and other Strategic Transactions | Optum Health
Disposition and Held for Sale [Line Items]
Gains on dispositions and other strategic transactions	1,400
Dispositions and other Strategic Transactions | UnitedHealthcare
Disposition and Held for Sale [Line Items]
Gains on dispositions and other strategic transactions	1,100
Dispositions and other Strategic Transactions | Optum Insight
Disposition and Held for Sale [Line Items]
Gains on dispositions and other strategic transactions	$ 800

Dispositions and Held for Sal_4

Dispositions and Held for Sale (Details) - USD ($) $ in Millions	Dec. 31, 2024	Feb. 06, 2024
Brazil Disposal Group
Disposition and Held for Sale [Line Items]
Cash and cash equivalents		$ 778
Accounts receivable and other current assets		515
Long-term investments		788
Property, equipment and capitalized software		1,052
Deferred tax assets		1,035
Goodwill and other intangible assets		317
Other long-term assets		439
Remeasurement of assets of businesses held for sale to fair value less cost to sell		0
Total assets		4,924
Medical costs payable		701
Accounts payable and other current liabilities		834
Other long-term liabilities		136
Total liabilities		$ 1,671
Businesses Held for Sale
Disposition and Held for Sale [Line Items]
Cash and cash equivalents	$ 219
Accounts receivable and other current assets	573
Long-term investments	41
Property, equipment and capitalized software	641
Deferred tax assets	0
Goodwill and other intangible assets	413
Other long-term assets	231
Remeasurement of assets of businesses held for sale to fair value less cost to sell	(1,224)
Total assets	894
Medical costs payable	179
Accounts payable and other current liabilities	338
Other long-term liabilities	504
Total liabilities	1,021
Foreign currency translation loss	(855)
Noncontrolling interests included in determination of remeasurement losses	$ 56

Segment Financial Information_3

Segment Financial Information (Narrative) (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement [Line Items]
Number of Reportable Segments	4
UNITED STATES
Statement [Line Items]
Disclosure on Geographic Areas Percentage of Revenue from External Customers	99%	97%	97%
Disclosure on Geographic Areas Percentage of Long Lived Assets	92%	82%
Revenues [Member] | CMS [Member] | Revenue Benchmark
Statement [Line Items]
Concentration Risk, Percentage	40%	40%	38%

Segment Financial Information_4

Segment Financial Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement [Line Items]
Premiums, revenues - unaffiliated customers	$ 308,810	$ 290,827	$ 257,157
Investment and other income	5,202	4,089	2,030
Total revenues	400,278	371,622	324,162
Total operating costs	367,991	339,264	295,727
Earnings from operations	32,287	32,358	28,435
Interest expense	(3,906)	(3,246)	(2,092)
Loss on sale of subsidiary and subsidiaries held for sale	(8,310)	0	0
Earnings before income taxes	20,071	29,112	26,343
Total assets	298,278	273,720	245,705
Segment, Expenditure, Addition to Long-Lived Assets	3,499	3,386	2,802
Depreciation and amortization	4,099	3,972	3,400
Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	50,226	42,583	37,424
Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	36,040	34,123	27,551
Optum
Statement [Line Items]
Investment and other income	2,789	1,838	1,107
Total revenues	252,957	226,635	182,768
Total operating costs	236,254	210,692	168,712
Earnings from operations	16,703	15,943	14,056
Interest expense	0	0	0
Loss on sale of subsidiary and subsidiaries held for sale	0
Earnings before income taxes	16,703	15,943	14,056
Total assets	190,010	174,871	147,516
Segment, Expenditure, Addition to Long-Lived Assets	2,718	2,520	2,003
Depreciation and amortization	3,210	2,983	2,427
Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	308,810	290,827	257,157
Total revenues	395,076	367,533	322,132
Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	50,226	42,583	37,424
Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	36,040	34,123	27,551
Unaffiliated Customers | Optum
Statement [Line Items]
Premiums, revenues - unaffiliated customers	22,806	21,775	18,374
Total revenues	99,281	88,424	73,314
Unaffiliated Customers | Optum | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	50,226	42,583	37,424
Unaffiliated Customers | Optum | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	26,249	24,066	17,516
Affiliated Customers
Statement [Line Items]
Total revenues	0	0	0
Affiliated Customers | Optum
Statement [Line Items]
Total revenues	150,887	136,373	108,347
Operating Segments | UnitedHealthcare
Statement [Line Items]
Investment and other income	2,413	2,251	923
Total revenues	298,208	281,360	249,741
Total operating costs	282,624	264,945	235,362
Earnings from operations	15,584	16,415	14,379
Interest expense	0	0	0
Loss on sale of subsidiary and subsidiaries held for sale	8,310
Earnings before income taxes	7,274	16,415	14,379
Total assets	119,009	110,943	107,094
Segment, Expenditure, Addition to Long-Lived Assets	781	866	799
Depreciation and amortization	889	989	973
Operating Segments | Optum Health
Statement [Line Items]
Investment and other income	2,239	1,532	928
Total revenues	105,358	95,319	71,174
Total operating costs	97,588	88,759	65,142
Earnings from operations	7,770	6,560	6,032
Interest expense	0	0	0
Loss on sale of subsidiary and subsidiaries held for sale	0
Earnings before income taxes	7,770	6,560	6,032
Total assets	96,472	89,432	68,950
Segment, Expenditure, Addition to Long-Lived Assets	1,008	1,199	997
Depreciation and amortization	1,123	1,058	943
Operating Segments | Optum Insight
Statement [Line Items]
Investment and other income	236	114	117
Total revenues	18,757	18,932	14,581
Total operating costs	15,660	14,664	10,993
Earnings from operations	3,097	4,268	3,588
Interest expense	0	0	0
Loss on sale of subsidiary and subsidiaries held for sale	0
Earnings before income taxes	3,097	4,268	3,588
Total assets	34,452	34,173	31,090
Segment, Expenditure, Addition to Long-Lived Assets	1,291	974	698
Depreciation and amortization	1,294	1,229	841
Operating Segments | Optum Rx
Statement [Line Items]
Investment and other income	314	192	62
Total revenues	133,231	116,087	99,773
Total operating costs	127,395	110,972	95,337
Earnings from operations	5,836	5,115	4,436
Interest expense	0	0	0
Loss on sale of subsidiary and subsidiaries held for sale	0
Earnings before income taxes	5,836	5,115	4,436
Total assets	59,086	51,266	47,476
Segment, Expenditure, Addition to Long-Lived Assets	419	347	308
Depreciation and amortization	793	696	643
Operating Segments | Unaffiliated Customers | UnitedHealthcare
Statement [Line Items]
Premiums, revenues - unaffiliated customers	286,004	269,052	238,783
Total revenues	295,795	279,109	248,818
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	9,791	10,057	10,035
Operating Segments | Unaffiliated Customers | Optum Health
Statement [Line Items]
Premiums, revenues - unaffiliated customers	22,806	21,775	18,374
Total revenues	39,236	36,091	29,363
Operating Segments | Unaffiliated Customers | Optum Health | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	277	207	72
Operating Segments | Unaffiliated Customers | Optum Health | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	16,153	14,109	10,917
Operating Segments | Unaffiliated Customers | Optum Insight
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0	0
Total revenues	6,640	7,922	5,176
Operating Segments | Unaffiliated Customers | Optum Insight | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	174	162	180
Operating Segments | Unaffiliated Customers | Optum Insight | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	6,466	7,760	4,996
Operating Segments | Unaffiliated Customers | Optum Rx
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0	0
Total revenues	53,405	44,411	38,775
Operating Segments | Unaffiliated Customers | Optum Rx | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	49,775	42,214	37,172
Operating Segments | Unaffiliated Customers | Optum Rx | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	3,630	2,197	1,603
Operating Segments | Affiliated Customers | UnitedHealthcare
Statement [Line Items]
Total revenues	0	0	0
Operating Segments | Affiliated Customers | Optum Health
Statement [Line Items]
Total revenues	63,883	57,696	40,883
Operating Segments | Affiliated Customers | Optum Insight
Statement [Line Items]
Total revenues	11,881	10,896	9,288
Operating Segments | Affiliated Customers | Optum Rx
Statement [Line Items]
Total revenues	79,512	71,484	60,936
Optum Eliminations
Statement [Line Items]
Investment and other income	0	0	0
Total revenues	(4,389)	(3,703)	(2,760)
Total operating costs	(4,389)	(3,703)	(2,760)
Earnings from operations	0	0	0
Interest expense	0	0	0
Loss on sale of subsidiary and subsidiaries held for sale	0
Earnings before income taxes	0	0	0
Total assets	0	0	0
Segment, Expenditure, Addition to Long-Lived Assets	0	0	0
Depreciation and amortization	0	0	0
Optum Eliminations | Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0	0
Total revenues	0	0	0
Optum Eliminations | Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0
Optum Eliminations | Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0
Optum Eliminations | Affiliated Customers
Statement [Line Items]
Total revenues	(4,389)	(3,703)	(2,760)
Corporate and Eliminations
Statement [Line Items]
Investment and other income	0	0	0
Total revenues	(150,887)	(136,373)	(108,347)
Total operating costs	(150,887)	(136,373)	(108,347)
Earnings from operations	0	0	0
Interest expense	(3,906)	(3,246)	(2,092)
Loss on sale of subsidiary and subsidiaries held for sale	0
Earnings before income taxes	(3,906)	(3,246)	(2,092)
Total assets	(10,741)	(12,094)	(8,905)
Segment, Expenditure, Addition to Long-Lived Assets	0	0	0
Depreciation and amortization	0	0	0
Corporate and Eliminations | Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0	0
Total revenues	0	0	0
Corporate and Eliminations | Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0
Corporate and Eliminations | Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0
Corporate and Eliminations | Affiliated Customers
Statement [Line Items]
Total revenues	$ (150,887)	$ (136,373)	$ (108,347)

Schedule I (Details)

Schedule I (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Condensed Financial Statements, Captions [Line Items]
Cash Dividends Paid to Parent, Consolidated Subsidiaries	$ 9,200	$ 8,000
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Cash Dividends Paid to Parent, Consolidated Subsidiaries	19,300	18,500	$ 15,600
Return of capital to parent company	21	639	$ 1,424
Long-term notes payable to subsidiaries	14,400
Short-term notes payable to subsidiaries	2,000	9,900
Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Other Long-term Debt	$ 700	$ 1,100

Schedule I Condensed Balance Sh

Schedule I Condensed Balance Sheets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 25,312	$ 25,427
Total current assets	85,779	78,437
Other assets	19,590	17,298
Total assets	298,278	273,720	$ 245,705
Current liabilities:
Accounts payable and accrued liabilities	34,337	31,958
Total current liabilities	103,769	99,054
Long-term debt, less current maturities	72,359	58,263
Other liabilities	15,939	14,463
Total liabilities	195,687	174,801
Commitments and contingencies (Note 4)
Shareholders’ equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value - 3,000 shares authorized; 915 and 924 issued and outstanding	9	9
Retained earnings	96,036	95,774
Accumulated other comprehensive loss	(3,387)	(7,027)
Total liabilities and shareholders’ equity	298,278	273,720
Parent Company [Member]
Current assets:
Cash and cash equivalents	234	776	$ 266	$ 2,167
Other current assets	411	570
Total current assets	645	1,346
Equity in net assets of subsidiaries	179,209	153,692
Other assets	920	831
Total assets	186,836	161,562
Current liabilities:
Accounts payable and accrued liabilities	1,501	1,116
Short-term notes payable to subsidiaries	2,000	9,900
Short-term borrowings and current maturities of long-term debt	4,348	4,086
Total current liabilities	7,865	15,089
Long-term debt, less current maturities	71,831	57,387
Long-term notes payable to subsidiaries	14,400
Other liabilities	77	330
Total liabilities	94,178	72,806
Shareholders’ equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value - 3,000 shares authorized; 915 and 924 issued and outstanding	9	9
Retained earnings	96,036	95,774
Accumulated other comprehensive loss	(3,387)	(7,027)
Total UnitedHealth Group shareholders’ equity	92,658	88,756
Total liabilities and shareholders’ equity	186,836	161,562
Parent Company [Member] | Subsidiaries [Member]
Current assets:
Long-term notes receivable from subsidiaries	6,062	5,693
Current liabilities:
Short-term notes payable to subsidiaries	2,016	9,887
Long-term notes payable to subsidiaries	$ 14,405	$ 0

Schedule I Balance Sheet Docume

Schedule I Balance Sheet Document (Details) - $ / shares shares in Millions	Dec. 31, 2024	Dec. 31, 2023
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000	3,000
Common stock, shares issued	915	924
Common Stock, shares outstanding	915	924
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10	10
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Parent Company [Member]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000	3,000
Common stock, shares issued	915	924
Common Stock, shares outstanding	915	924
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10	10
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Schedule I Condensed Statement

Schedule I Condensed Statement of Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Investment and other income	$ 5,202	$ 4,089	$ 2,030
Total revenues	400,278	371,622	324,162
Operating costs:
Interest expense	3,906	3,246	2,092
Total operating costs	367,991	339,264	295,727
Benefit for income taxes	4,829	5,968	5,704
Net earnings	14,405	22,381	20,120
Other comprehensive (loss) income	3,640	1,366	(3,009)
Comprehensive income	18,045	23,747	17,111
Parent Company [Member]
Revenues:
Investment and other income	368	312	255
Total revenues	368	312	255
Operating costs:
Operating costs	108	35	121
Interest expense	4,544	3,469	2,110
Total operating costs	4,652	3,504	2,231
Loss before income taxes	(4,284)	(3,192)	(1,976)
Benefit for income taxes	1,032	654	429
Loss of parent company	(3,252)	(2,538)	(1,547)
Equity in undistributed income of subsidiaries	17,657	24,919	21,667
Net earnings	14,405	22,381	20,120
Other comprehensive (loss) income	3,640	1,366	(3,009)
Comprehensive income	$ 18,045	$ 23,747	$ 17,111

Schedule I Statement of Cash Fl

Schedule I Statement of Cash Flows (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating activities
Cash flows from operating activities	$ 24,204	$ 29,068	$ 26,206
Investing activities
Cash paid for acquisitions and other transactions	(13,408)	(10,136)	(21,458)
Cash received from dispositions and other strategic transactions, net	2,041	685	3,414
Other, net	1,667	960	793
Cash flows used for investing activities	(20,527)	(15,574)	(28,476)
Financing activities
Common stock repurchases	(9,000)	(8,000)	(7,000)
Proceeds from common stock issuances	1,846	1,353	1,253
(Repayments of) proceeds from short-term borrowings, net	(151)	11	732
Proceeds from issuance of long-term debt	17,811	6,394	14,819
Repayments of long-term debt	(3,000)	(2,125)	(3,015)
Other, net	(1,645)	(1,150)	(1,944)
Cash flows from (used for) financing activities	(3,512)	(11,529)	4,226
(Decrease) increase in cash and cash equivalents	(115)	2,062	1,990
Cash and cash equivalents, beginning of period	25,427
Cash and cash equivalents, end of period	25,312	25,427
Supplemental cash flow disclosures
Cash paid for interest	3,594	3,035	1,945
Cash paid for income taxes	4,620	6,078	5,222
Parent Company [Member]
Operating activities
Cash flows from operating activities	4,852	17,443	14,754
Investing activities
Issuances of notes to subsidiaries	(349)	(41)	(567)
Repayments of notes to subsidiaries	225	817	281
Cash paid for acquisitions and other transactions	(13,750)	(8,144)	(20,728)
Return of capital to parent company	21	639	1,424
Capital contributions to subsidiaries	0	(2,472)	(570)
Cash received from dispositions and other strategic transactions, net	2,444	624	2,787
Other, net	30	286	0
Cash flows used for investing activities	(11,379)	(8,291)	(17,373)
Financing activities
Common stock repurchases	(9,000)	(8,000)	(7,000)
Proceeds from common stock issuances	1,846	1,353	1,253
Cash dividends paid	(7,533)	(6,761)	(5,991)
(Repayments of) proceeds from short-term borrowings, net	(151)	11	732
Proceeds from issuance of long-term debt	17,811	6,394	14,819
Repayments of long-term debt	(3,000)	(2,125)	(3,015)
(Repayments of) proceeds from notes from short-term notes from subsidiaries, net	(7,966)	1,188	594
Proceeds from long-term notes from subsidiaries	14,396	0	0
Repayments of long-term notes from subsidiaries	(28)	0	0
Other, net	(390)	(702)	(674)
Cash flows from (used for) financing activities	5,985	(8,642)	718
(Decrease) increase in cash and cash equivalents	(542)	510	(1,901)
Cash and cash equivalents, beginning of period	776	266	2,167
Cash and cash equivalents, end of period	234	776	266
Supplemental cash flow disclosures
Cash paid for interest	4,241	3,257	1,969
Cash paid for income taxes	$ 2,450	$ 4,426	$ 4,298

Schedule I Maturities of Short-

Schedule I Maturities of Short-Term Borrowings and Long-Term Debt (Details) $ in Millions	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
2025	$ 4,548
2026	3,756
2027	3,531
2028	3,106
2029	3,656
Thereafter	59,908
Parent Company [Member]
Debt Instrument [Line Items]
2025	4,350
2026	3,650
2027	3,425
2028	3,000
2029	3,550
Thereafter	$ 59,802